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ABSTRACT 
 Soluble antigen arrays (SAgAs) were used to treat experimental autoimmune 
encephalomyelitis (EAE), which is a mouse model for multiple sclerosis (MS). SAgAs 
offer a targeted therapy for MS, which is not present in current therapies. The different 
routes of administration, injection volume, dosing amount, and dosing schedule were 
explored to find that pulmonary instillation of SAgAs at 50 µL on a 200 nMol PLP basis 
on days 4, 7, and 10 of the study are most efficacious. With the next study, the different 
components of SAgAs (hyaluronic acid, PLP, LABL, and bifunctional peptide inhibitor) 
were also investigated via pulmonary delivery to find that PLP and SAgAs decreased the 
symptoms of EAE the most. PLP, HA-PLP, and SAgAs were further explored either via 
subcutaneous injection or pulmonary instillation to find that HA-PLP and SAgAs 
decreased disease progression in mice with EAE. Cytokine panels were also used to 
determine if tolerance was induced in these mice via the measurements of pro- and anti-
inflammatory cytokines. Lastly, lung histology was explored to find signs of inflammation. 
Overall, SAgAs are found to be very efficacious in treating mice via PI and the presence 
of PLP makes a big difference. Other methods like the presence of regulatory T cells 
need to be used to find additional signs of tolerance induction in future studies. 
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Chapter 1: 
Outline 
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 The overall goal of this thesis is to find the optimal way to deliver Soluble Antigen 
Arrays (SAgAs) to mice with experimental autoimmune encephalomyelitis (EAE) to 
ameliorate disease. EAE is the mouse model of multiple sclerosis, which is a 
neurodegenerative disease caused by demyelination of neurons. While there are many 
existing treatments for multiple sclerosis, they lack specificity in targeting just immune 
cells that cause disease. SAgAs were developed to target the immune cells that target 
proteolipid protein (PLP139-151), which is one of the major epitopes on myelin sheath. The 
additional peptide co-delivered with PLP is LABL, which binds to the cell surface 
receptor ICAM-1. Evidence from our lab and from collaborators with Professor Siahaan 
suggest SAgAs can block immune cell interaction, but only when both PLP and LABL 
are co-delivered. Since this therapy has a specific antigen epitopes (PLP139-151), the hope 
is to decrease immunological activity of PLP-specific cells, but not induce systemic 
immune suppression.  
 Chapter 2 addresses the background of multiple sclerosis, existing treatments, 
the murine model EAE, and the proposed SAgA treatment. The co-delivery of PLP and 
LABL and how the sites of delivery may affect the immune system is discussed, offering 
a comparison to traditional ASIT. The three studies that were run in this dissertation are 
reviewed briefly: (1) varying schedule, dose, amount, and routes of administration of 
SAgAs; (2) delivering the components of SAgA via the most effective route of 
administration and observing the disease progression via cytokine profiles; and (3) 
investigating the necessity of delivering PLP as an array and co-delivering LABL with 
PLP as an array.  
 In Chapter 3, the dose schedule, dose amount, dose volume, and routes of 
delivery of SAgA were varied to see which was the most effective in decreasing EAE 
disease symptoms. Historically, treatments were given on days 4, 7, and 10 of the study, 
but in this study, the idea of treating only on one of the days was explored. SAgAs have 
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also usually been dosed at 200 nMol PLP, but a 50 nMol PLP dose was also given to 
see if a full dose is necessary. The concentration of SAgA was increased 5-fold to see if 
a 20 µL injection would be comparable to the 100 µL injection that is usually given. 
Lastly, the routes of administration were also varied from the typical subcutaneous 
injections given between the mouse shoulder blades to subcutaneous injections given 
between the hind quarters, intramuscular injections given in the upper limbs of the 
mouse, intramuscular injections given in the lower limbs of the mouse, intraperitoneal 
injections, intravenous tail vein injections, and pulmonary instillation.  
 Chapter 4 focused on delivering the components of SAgA via the optimized 
treatment regimen, including the best route of delivery. SAgAs are made up of 
hyaluronic acid, LABL, and PLP, so these were the three main controls given to the 
mice. Additionally, there is a small molecule version of the SAgA, called a bifunctional 
peptide inhibitor (BPI), that was also given as treatment to the mice. BPI contains PLP 
and LABL, connected via a short linker. Instead of being presented on an array, like the 
SAgAs, BPI is a smaller molecule version for comparison. Also, since SAgA was 
developed from studies on BPI, it was used as a control to see if SAgAs still ameliorate 
disease as well as BPI when given via a different route of delivery. A cytokine panel was 
used to see how the splenocytes of the treated reacted to PLP. 
 The results discussed in chapter 4 gave the impetus for the study design in 
chapter 5. While SAgA decreased EAE scores the most, PLP alone was also seen to be 
slightly effective. As a result, this study explored the necessity of co-delivering PLP and 
LABL. PLP alone was also presented in an array using the same hyaluronic acid 
backbone (HA-PLP). Lastly, PLP, HA-PLP, and SAgA were dosed via the route of 
delivery typically used for studies preceding chapter 3 and compared the route of 
delivery that this dissertation identified to be the most optimal. Thus, the study presented 
in chapter 5 explores the effect that PLP can have in ameliorating disease. Another 
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cytokine panel was used at the end of the study, where both pro-inflammatory and anti-
inflammatory cytokines were presented to see what kind of effects the various 
treatments had on the splenocytes of the mice. 
 Chapter 6 offers concluding remarks of the thesis. Interpretations from each 
study are summarized, as well as future directions for this project. These remarks can be 
used to gain a further understanding of treating EAE with SAgAs. 
 Overall, this dissertation will provide a better understanding of EAE progression, 
and what components of SAgA are necessary in a treatment to ameliorate disease. The 
optimal route of administration will provide insight into a possible mechanism of disease. 
Finally, the necessity of PLP presented on an array and being co-delivered with LABL in 
treating mice will also be further questioned.  
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Chapter 2: 
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 Multiple Sclerosis (MS) is an autoimmune disease where the myelin sheath is 
broken down by immune cells. MS-patients experience varying degrees of physiological 
and neurological symptoms. Loss of vision is reported as one of the first manifestations, 
but as the disease progresses, symptoms also intensify to loss of balance, paralysis, 
muscle spasms, loss of brain function, etc1. While there are existing treatments that can 
decrease symptoms, the disease will still progress over time. Instead of treating the 
disease symptoms, another approach is to induce immune tolerance. 
 In order to study possible treatments, a murine model of MS named experimental 
autoimmune encephalomyelitis (EAE) is often utilized. EAE is induced in female SJL 
mice because there is a high T cell count in SJL mice2. There are four subtypes of MS: 
relapsing-remitting, secondary progressive, primary progressive, and progressive 
relapsing (Figure 1)3. In most cases, MS starts as a relapsing-remitting subtype, where 
there are periods of remission and then periods of relapse, but the baseline never 
returns to a point where no symptoms are felt. As the disease progresses, there are 
fewer periods of relapse as the disease symptoms increase, which is the progressive-
relapsing subtype4. At the peak of the disease, there are no periods of relapse and the 
disease just continues progressing, which is the primary progressive subtype. This 
progression from relapsing-remitting MS to primary progressive MS is known as the 
secondary progressive subtype of MS. About 85% of patients with MS have relapsing-
remitting MS since this subtype lasts for the longest period of time before disease 
progresses5.  
 To reflect relapsing-remitting MS in the animal model, proteolipid protein (PLP139-
151), one of the three main epitopes on myelin sheath, is used to induce disease6. The 
use of other epitopes can induce different subtypes of MS. At the end of the month-long 
PLP-induced EAE study, the animals return to baseline, followed by one period of 
relapse.  EAE induced with myelin oligodendrocyte glycoprotein (MOG) causes 
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symptoms similar to primary progressive MS7. At the end of the MOG-EAE study, mice 
are at the peak of disease, with no sign of improvement (Table 1). 
2.1 Existing Therapies for MS 
 Disease modifying treatments to help alleviate symptoms of MS include: 
natalizumab (Tysabri®), glatiramer acetate (Copaxone®), fingolimod (Gilyena®), and 
interferon beta (Avonex®, Rebif®, and Cinnovex®). Natalizumab is the only monoclonal 
antibody currently available to treat MS. It binds to the α1β2 integrin on the blood brain 
barrier to inhibit monocytes from passing into the brain. As a result, there is a chance for 
the brain to be infected with the JC virus. The JC virus causes progressive multifocal 
leukoencephalopathy in an immunosuppressed patient, which is characterized by 
inflammation of the white matter of the brain. Patients must now be screened for the JC 
virus before natalizumab can be administered8. Another treatment, glatiramer acetate, is 
made up of four amino acids (EAKY) that are most commonly found in the proteins that 
make up myelin sheath. It was initially tested as an antigen to induce EAE, but it was 
later found to ameliorate the disease instead, and it is now used as a therapeutic. 
Initially, glatiramer acetate was thought to act as a competitive inhibitor against myelin 
sheath, but the latest data indicates that it shifts the Th1 response to an anti-
inflammatory Th2 response9. Fingolimod acts very differently in comparison to 
natalizumab and glatiramer acetate. It sequesters lymphocytes in lymph nodes, so T cell 
expansion is less likely to occur and less T cells migrate into the periphery to attack the 
neurological tissue10. Interferon beta balances both pro- and anti-inflammatory cytokines, 
thus reducing neuronal inflammation (Table 2)9.  
 All of the existing treatments have been screened through the EAE murine 
model. In this induced disease model, the mice are vaccinated with an emulsion 
containing PLP and incomplete Freund’s adjuvant. EAE was initially used to portray 
demyelinating diseases, but has transformed into the main animal model used for 
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multiple sclerosis3. Spontaneous EAE models do exist, but they are difficult to track in 
animal studies when it is unclear when to start treatment and when disease actually 
manifests itself in the mice. Another criticism of EAE is that once these treatments are 
given in humans, there can be unexpected immunogenic responses. Also, since EAE is 
given via a vaccination and MS is spontaneous, the mechanism of the disease differs, 
meaning that treatments given in mice with EAE may work for that specific mechanism 
of disease, but not for MS.  
2.2 Introducing SAgAs to Treat EAE 
 Existing treatments lessen the symptoms over time, but do not induce immune 
tolerance. A novel therapeutic has been introduced in the Berkland lab, called soluble 
antigen array (SAgA)11. SAgAs are composed of hyaluronic acid (HA), PLP139-151, and 
LABL. HA is a biodegradable polymer that is already present in the extracellular matrix 
and in lymph. PLP139-151 is the antigenic peptide epitope on myelin sheath used to induce 
disease. LABL is a peptide derived from leukocyte function-associated antigen-1 (LFA-1) 
and is an intercellular adhesion molecule-1 (ICAM-1) ligand. LABL is a part of the I 
domain of LFA-1, which is what binds with domain 1 of ICAM-112. The LFA-1/ICAM-1 
interaction allows T cells and dendritic cells to adhere to one another and form an 
immunological synapse. SAgAs were designed to co-deliver PLP139-151 and LABL in the 
format of an array to block the immunological synapse between a dendritic cell that 
presents myelin sheath as ‘non-self’ and the cognate T cell to inhibit T cell expansion. 
This allows for a targeted approach to decrease immunological activity in the case of 
autoimmune diseases. SAgA technology was based on a smaller version called 
bifunctional peptide inhibitor (BPI), which was developed in the Siahaan lab12. BPI is 
composed of LABL and PLP, with a linker in between. Since T cell receptors are known 
to cluster during an immunological synapse, SAgAs were designed to block multiple 
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receptors with one molecule. Additionally, the larger molecule was hypothesized to have 
a longer half-life in the body.  
 When the SAgAs were designed, a concept known as ‘Dintzis rules’ was followed 
to favor a tolerogenic response (Table 3)13. Dintzis rules indicate that a soluble, flexible 
polymer that is <100 kDa with antigen spacing of 2 – 7 nm with ~5 antigens/kDa must be 
utilized to induce tolerance. A linear polymer with ~10 antigenic PLP epitopes was used. 
SAgAs contain HA, which is a soluble flexible polymer. There were also two sizes of 
SAgAs used in early experiments, 30 kD and 50 kD SAgA11. Both of the sizes of SAgA 
decreased clinical scores of EAE, but the 30 kD SAgA delayed the onset of the disease 
by a few days. In addition, there are two peptides on SAgA as previous data had shown 
that co-delivery of PLP and LABL decreased the symptoms of EAE. Instead of blanket 
immunosuppression, SAgAs may offer a more targeted treatment for EAE, and 
ultimately MS. 
2.3 SAgA Treatment as Antigen Specific Immunotherapy to Induce Tolerance 
 One school of thought in developing the SAgA treatment is to follow a similar 
methodology used to induce tolerance to allergens. In antigen-specific immunotherapy 
(ASIT), patients are exposed to the allergen starting at low quantities, increasing over 
time14. The goal is to decrease IgE response to the allergen, thus, inducing tolerance to 
this antigen over the course of many months or years. Thus, the overall goal of SAgA 
treatment was to shift cytokine and cellular responses towards tolerance and away from 
inflammatory markers associated with PLP-induced EAE. Basically, the body is being 
reprogrammed to avoid an immunogenic response against PLP by using an optimized 
SAgA treatment regimen. 
2.3.1 ASIT Routes of Administration 
 ASIT typically uses subcutaneous injections of allergen. Intravenous and 
intranodal injections in ASIT can increase anaphylaxis events, as the intravenously 
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injected allergens are more likely to passively diffuse systemically and the intranodal 
injections may be too high of a targeted dose, inducing anaphylaxis shock14. Intranodal 
delivery is attractive, because it has been shown to take a shorter period of time to 
induce tolerance to the allergen. Other mucosal delivery routes are also being 
considered, since mucosal surfaces have been hypothesized to induce a tolerogenic 
phenotype15. The most common mucosal delivery routes investigated are sublingual 
immunotherapy and oral immunotherapy. While the sublingual route can be applied to 
many different types of allergens, the oral route is thought to be best for food allergens. 
Patient compliance may also be higher as it is much easier to take a pill instead of 
having someone administer an injection16. 
2.3.2 ASIT Dosing Regimen 
 The amount of time allergy therapy requires is a huge factor in patient 
compliance as well. Subcutaneous ASIT, for example, can take up to 3 years to 
complete the therapy, whereas clinical studies suggest that timeline can be shortened 
down to 6-8 months with intranodal delivery. Intranodal delivery is, however, more 
invasive, so that could decrease patient compliance. Sublingual immunotherapy has 
reported a shorter timeline (14 months), and it is less likely to induce anaphylaxis in 
comparison to an injection. While a timeline for effective oral ASIT has yet to be 
identified, reports suggest decreased anaphylaxis compared to injections14,16. 
2.3.3 SAgA Route of Administration 
 The potential for ASIT in MS is still being debated, but one school of thought is 
that MS is a systemic disease in early stages and localizes to the lymph nodes close to 
the central nervous system (CNS) in later stages17. In order to find an effective delivery 
route of SAgAs, various routes of administration have been explored. In this dissertation, 
SAgAs were delivered subcutaneously and intramuscularly, both near the CNS and 
away from the CNS to determine the optimal route of administration. Additionally, SAgAs 
	   11	  
were delivered intravenously and intraperitoneally to study systemic delivery and 
delivery to lymph nodes away from the CNS, respectively. Subcutaneous delivery allows 
for slow absorption into the body, compared to immediate systemic delivery of the 
therapeutic via intravenous delivery. On the other hand, intramuscular delivery may favor 
a depot at the injection site, potentially decreasing the chance of anaphylaxis.  
 If SAgAs are most potent via delivery to the lymph nodes, various mechanisms of 
transport should be considered (Figure 2). HA is known to travel to the lymph nodes 
when injected in the mouse footpad, as shown by Bagby, et al18. In this study, 70-kD HA 
seemed to have the longest residence time in the draining lymph node, which is why 80-
kD SAgA was designed by our lab. Since SAgAs contain peptides as well, the behavior 
may differ from that of HA. Another size restriction to consider is that mentioned by Rao 
et al19. If a molecule has a hydrodynamic radius less than 10 nm, it may tend to absorb 
into the circulatory system. If between 10 nm to 50 nm, the molecule should travel to the 
lymph nodes, and when the molecules are greater than 50 nm in size, they tend to stay 
at the injection site. Subsequently, our lab discovered 50-kD SAgA was about 10 nm in 
size and 80-kD SAgA were larger. In vivo results published previously also showed that 
the smaller SAgA decreased EAE symptoms, thus the 50-kD SAgA was chosen in this 
dissertation11.  
 One last route of delivery that we considered was pulmonary instillation (PI) of 
SAgAs in mice with EAE. PI of SAgAs was motivated by the potential for mucosal 
tolerization and the recent ‘Hub and Spoke’ model, which says that T cells are given 
instructions on where to go (i.e. are licensed) in the lung before they are sent out to the 
periphery20,21. Delivery of a therapeutic to the lung may allow for maximal interaction with 
autoreactive T cells, according to this model. Whether this route will induce tolerance is 
still unknown.  
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2.4 Conclusions 
 This dissertation concentrates on finding the optimal route and regimen to deliver 
SAgAs. Approaches for treating allergies were hypothesized to be a guide for treating 
autoimmune diseases. Both seek to induce tolerance to the antigen, whether it be in the 
form of an allergy shot or via SAgAs to treat EAE. The typical route of delivery for ASIT 
is a subcutaneous injection, but other routes like intranodal, sublingual, and oral are 
being explored. In order to find the optimal SAgA route of administration, various 
parenteral routes (subcutaneous, intramuscular, intravenous, and intraperitoneal) and 
pulmonary instillation were considered. The dose schedule, dose, and injection volume 
were also systematically explored. The most effective route of administration was then 
used to explore the mechanism of action by comparing the individual components to 
SAgA molecules. Lastly, the necessity of co-delivery of PLP and LABL and delivery of 
these peptides with HA was explored to help deduce a mechanism of action. 
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Table 1. Subtypes of multiple sclerosis and EAE. 
 
Multiple 
Sclerosis 
Subtype 
Antigen Used Rodent Type Strain Reference 
6 
4 relapsing-remitting 
Proteolipod Protein (PLP 
139-151) Mouse SJL/J 
22 
relapsing-
remitting 
adoptive transfer of Myelin 
Basic Protein Mouse SJL/J 7 
relapsing-
remitting 
Proteolipod Protein (PLP 
139-151) Mouse 
PLP-specific 
Transgenic mice 7 
primary 
progressive 
Myelin Oligodendrocyte 
Glycoprotein (MOG 35-55) Mouse transgenic OGE 23 
7 
24 primary progressive 
Myelin Oligodendrocyte 
Glycoprotein (MOG 35-55) Mouse C57BL/6 22 
primary 
progressive 
Myelin Oligodendrocyte 
Glycoprotein (MOG 35-55) Mouse 
transgenic IL-32a 
mice 25 
primary 
progressive 
Myelin Oligodendrocyte 
Glycoprotein (MOG 35-55) Mouse 
transgenic CRP 
mice 26 
primary 
progressive 
Myelin Oligodendrocyte 
Glycoprotein (MOG 35-55) Mouse 
TCR transgenic 
mice 27 
secondary 
progressive 
synegic spinal cord 
homogenate Mouse Biozzi ABH 28 
29 relapsing-
remitting 
Guinea Pig Spinal Cord 
Homogenate Rat Lewis 30 
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Table 2. Existing treatments of multiple sclerosis. 
	  
 
Existing 
Treatment Mechanism of Action 
Expected Site of 
Action 
Natalizumab 
Binds to α1β2 integrin on the 
blood brain barrier to inhibit 
monocytes from crossing into the 
brain 
Blood brain barrier 
Glatiramer acetate Shifts Th1 response to anti-inflammatory Th2 response Periphery 
Fingolimod Sequesters T cells to the lymph node so they cannot leave Lymph node 
Interferon-β Balances pro- and anti-inflammatory cytokines Periphery 
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Figure 1. Score profiles of the different types of multiple sclerosis. (A) Relapsing-
remitting MS. (B) Primary progressive MS. (C) Secondary progressive MS. 
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Polymer properties Immunogenic SAgA Tolerogenic 
Mw >100 kDa <100 kDa 
Antigen Density/kDa >10 ~5 
Antigen Spacing 2-7 nm 2-7 nm 
Structure Rigid Flexible 
Solubility Poorly soluble Highly soluble 
	  
Table 3. Dintzis rules for immune response. 
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Figure 2. Depending on the size, SAgAs will either (1) absorb into the blood, (2) drain to 
the lymph nodes, or (3) remain at the injection site.  
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Chapter 3: 
Routes of Administration and Dose Optimization 
of Soluble Antigen Arrays in Mice with 
Experimental Autoimmune Encephalomyelitis 
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3.1 Introduction 
 Multiple sclerosis (MS), an autoimmune disease that destroys the myelin sheath, 
impacts the patient both physically and mentally1. Loss of vision, varying degrees of 
paralysis, loss of balance, and lack of coordination constitute the most common physical 
symptoms. Mental symptoms include slurring of speech and cognitive difficulties. The 
onset of disease typically occurs in young adults, but the disease continues into 
adulthood. Current therapeutic interventions can mitigate symptoms but none address 
the underlying immune response specific to offending myelin autoantigens. 
 MS can be classified into the following types: (1) secondary progressive, (2) 
primary progressive, (3) progressive relapsing, and (4) relapsing remitting. Because 
relapsing remitting MS (RRMS) affects 80% of patients with MS, current treatments have 
focused on this form of the disease2. In RRMS, the symptoms manifest periodically. In a 
period of relapse, the patient is acutely aware of the symptoms, but feels them to a 
lesser degree during periods of remission. Over time, symptoms are continually 
perceived even during periods of remission, a development indicative of progressive 
RRMS.  
 Not much is known about the cause of MS in humans. One theory asserts that 
MS is a systemic disease in its early stages, and in the later stages MS is localized to 
the lymph nodes located close to the spinal cord3. As a result, designing a treatment that 
can be active at the lymph nodes may be important. Another theory suggests that T cells 
are licensed (programmed with a tropism for the cervical lymph nodes) in the lungs 
before being sent to the CNS, alluding that an important site of intervention may be in 
the lungs, instead of the cervical lymph nodes4,5. 
 The animal model typically used to mimic MS is EAE, where young mice are 
given adjuvant along with specific epitopes of PLP (proteolipid protein) or other antigens 
from proteins that make up myelin sheath6-8. In this PLP-induced EAE model, one cycle 
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of MS-like symptoms is followed by remission over a 25-day period. Clinical scores are 
assigned by the degree of paralysis and balance. Other symptoms usually present in 
MS, such as cognitive ability, are difficult to measure in mice. The severity of EAE is 
measured by the clinical scores given to each mouse, with an increase in score 
indicating an increasing degree of paralysis, ascending from the tail to the hind-limbs 
and then the fore-limbs as the disease worsens. 
 The available treatments for MS are known to slow the disease progression and 
to manage specific symptoms. In early stages of the illness, disease-modifying 
treatments like interferon-β, glatiramer acetate, mitoxantrone, and natalizumab are 
prescribed.  Natalizumab, also known as Tysabri®, inhibits transit of lymphocytes across 
the blood-brain barrier. In the later stages of the disease, very low dose cancer 
chemotherapeutics may be used to suppress the immune system while minimizing 
systemic toxicity9. Another approved treatment, fingolimod (Gilenya®), sequesters 
lymphocytes within lymph nodes, thereby restricting further destruction of the myelin 
sheath10. This leaves the patient open to opportunistic infections, however, as is the 
case with global immunosuppressors. Designing therapies that specifically target 
lymphocytes associated with MS or that induce tolerance to autoantigens by inhibiting 
costimulation during autoantigen recognition may further stymie the progression of the 
disease. 
 Our lab has developed Soluble Antigen Arrays (SAgAs), composed of a 
hyaluronic acid (HA) backbone with grafted autoantigen (e.g. PLP epitope) and a second 
peptide, such as an ICAM-1 ligand (LABL) (Table 3.1)11. The size of SAgAs can be 
designed to drain with interstitial fluid and fit through the pores of lymphatic vessels, 
which range between 10 nm and 100 nm12. At least three factors affect SAgA drainage 
and, ultimately, absorption: the site of injection, diffusion of the SAgA, and local vascular 
and lymphatic network. After subcutaneous injection, for example, HA can drain to lymph 
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nodes and certain molecular weights of HA can have a long retention time13. By varying 
the route of administration (site of injection and the type of injection), we investigated 
which route offers the best efficacy. SAgA treatment alleviates the clinical symptoms of 
EAE, yet the mechanism of action is still unclear11. Here, variations in dose schedule, 
SAgA dose, injection volume, and different routes of administration were tested to 
improve understanding of the clinical mechanism. Intramuscular (IM), subcutaneous 
(SC), intraperitoneal (IP), intravenous (IV), and pulmonary instillation (PI) routes of 
administration were studied.  
3.2 Materials and Methods 
3.2.1 Peptide Synthesis. Peptides were made using an automated solid phase peptide 
synthesizer (Pioneer; Perceptive Biosystems, Framingham, MA). 9-
florenylmethyloxycarbonyl-protected amino acids were used to synthesize both PLP139-
151 and LABL. In order to conjugate these peptides onto HA, an aminooxy (Ao) group 
was added to the N-terminus of PLP and LABL in the peptide synthesizer. Peptides were 
cleaved off of the resin using trifluoroacetic acid (TFA) and scavengers.  
 The peptides were then purified using a C18 semipreparative column (Higgins 
Analytical, Proto200, 5 µm, 200 Å, 250x20mm) with reversed-phase high performance 
liquid chromatography (HPLC). A gradient method was used to purify the peptides, with 
an aqueous mobile phase A (94.9% d.d. H2O, 5% acetonitrile, and 0.1% TFA) and an 
organic mobile phase B (99.9% acetonitrile and 0.1% TFA). The purity of the peptides 
was analyzed using HPLC on a C18 analytical column (Higgins Analytical, Proto200, 5 
µm, 200 Å, 250x4.6mm) with the same mobile phases and similar gradient program. The 
molecular weight of the peptides was identified using an electrospray ionization time-of-
flight mass spectrometer (Supplemental Figure 3.1). 
3.2.2 SAgA Synthesis. After the peptides were purified, they were then conjugated onto 
HA. A 2-mg/mL solution of HA (16.9 kDa, 16 kDa, Lifecore Biomedical, Chaska, MN) 
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was made using 20 mM acetate buffer at pH 5.5. AoLABL and AoPLP were mixed 
together in equal molar proportions, then added to the 2-mg/mL HA solution at a ratio of 
1 aminooxy-peptide to 2 monomers of HA. The reaction continued for 24 hours, and then 
the reaction was dialyzed (MW 3500, 6000-8000) against purified water for 24 hours. 
Samples were frozen and dried using a lyophilizer. 
 SAgAs were further analyzed to check peptide content. The SAgAs were 
dissolved in 0.1-N HCl at pH 1 for at least 4 hours to cleave the peptides. Using a 
calibration curve of free AoLABL and AoPLP at various concentrations, the amount of 
peptides in SAgAs were determined via reversed-phase HPLC on a C18 analytical 
column. 
3.2.3 Dynamic Light Scattering (DLS). The size distribution of SAgAs were determined 
using a Brookhaven Zeta-PALS at various concentrations (0.5 – 10 mg/mL) in PBS after 
they were filtered through a 0.45 µm PVDF membrane. Light scattering was detected at 
90° and using a laser operated at 658 nm. The hydrodynamic radius (Rh) was 
determined from the Stokes-Einstein equation: Rh=kbT/6πηDT, where kb is the 
Boltzmann’s constant, T is temperature (K), η is the solvent viscosity, and DT is the 
translational diffusion coefficient. The particle size was derived using the Stokes-Einstein 
equation and the autocorrelation function using a non-negatively constrained least 
squares (NNLS) deconvolution algorithm.  
3.2.4 EAE Model. The 6-8 week old female SJL/J mice for the Route of Administration 
study were purchased from Charles River Laboratories, Inc. (Wilmington, MA). The 3-
week old female SJL/J mice for the dosing study were purchased from Harlan 
Laboratories, Inc. (Indianapolis, IN). The mice were housed in a pathogen-free facility at 
the University of Kansas approved by the Association for Assessment and Accreditation 
of Laboratory Animal Care (AAALAC). All experimental procedures using live animals 
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have been reviewed and approved by the Institutional Animal Care and Use Committee 
(IACUC) at the University of Kansas.  
On Day 0 of the study, the SJL/J mice were induced with EAE through four 50-µL 
injections of an emulsion containing Incomplete Freund’s Adjuvant Oil (BD Difco 
Adjuvants, Franklin Lakes, NJ), Mycobacterium tuberculosis (BD Difco Adjuvants, 
Franklin Lakes, NJ), and 200 nMol of PLP per animal. The SC injections were given 
above each of the shoulder blades and the rear haunches of the mouse. Each animal 
was also given a 100-µL IP injection of 200 ng of pertussis toxin (List Biological 
Laboratories, Inc., Campbell, CA) on Days 0 and 2. The mice were weighed on each day 
of the 25-day study and were given a clinical score ranging between 0 and 5 from Day 7 
to the end of the study. The clinical score increases with disease progression. Scores 
increased in correlation with the level of paralysis, starting with the tail and advancing to 
the head. The following clinical score scale was used: 0 – no symptoms of disease were 
seen, 1 – limp tail and waddling gait, 2 – partial hind leg paralysis, 3 – paraplegia 
(complete hind leg paralysis), 4 – partial front leg paralysis, 5 – moribund or complete 
front leg paralysis. The mice were then treated on Days 4, 7, and 10 with 100 µL of 
SAgA (containing 200 nMol of PLP) on each treatment day, unless otherwise stated. 
There were 6 mice in each group, with three mice housed together per cage. All the 
statistical analysis was done on Prism GraphPad 5 software, using ANOVA analysis. 
3.2.5 Changing the Dose Schedule, Volume, and Amount of SAgA Treatment. EAE 
mice were treated on only one of the three days mentioned (day 4, 7, or 10). Days 4 and 
7 was chosen as a treatment day to monitor disease progression if treatment occurred 
prior to symptoms and day 10 was chosen to track the disease severity if treated after 
the symptoms were visible. SAgA was still given on a 200-nMol PLP basis using 100 uL 
per injection. Two other variables were changed in the study, the amount of SAgA given 
and the volume of the injection. One group of mice was treated on a 50-nMol PLP basis 
	   27	  
of SAgA (100 uL per injection) given on all three treatment days. Another group of mice 
was treated on a 200-nMol PLP basis of SAgA using 20 uL per injection given on all 
three treatment days. All of these injections were given in the Upper SC site. The same 
SAgA was used for each animal study and the PLP:LABL ratio (1:1) was kept the same 
in each study. 
 As a negative control, a group that only received phosphate buffered saline 
(PBS) as a treatment was included in each study. A group that received a SC SAgA 
injection in the upper back was also included as a positive control in each study since 
treatment route was used in previous11,14.  
3.2.6 Route of Administration EAE Study. The administration routes initially explored 
were IM, SC, and IP. More sites were then added to test whether clinical scores may 
improve if administering SAgAs near the upper lymph nodes, close to the spinal cord. As 
a result, the following injection sites were used: IP, Upper IM, Lower IM, Upper SC, and 
Lower SC  (Figure 3.1).  
 In a second component of the study, IV and pulmonary routes were also 
compared to the Upper SC delivery of SAgAs. A tail vein IV injection site was chosen to 
measure what the effect systemic delivery of SAgA would produce. SAgAs were given at 
a 200-nMol PLP basis at an injection volume of 100 µL.  For PI, SAgAs were given at a 
200 nMol PLP basis, but the injection volume was decreased to 50 µL due to the 
limitation in volume that can be safely delivered to lungs. Administration positive and 
negative controls were included for both studies as mentioned above. 
 For PI administration, each animal was anesthetized with inhaled isoflurane in an 
induction chamber.  After the mouse was fully anesthetized, the mouse was positioned 
with its back on a dosing board at approximately a 60° angle to a supine position using a 
thin wire to suspend them by their incisor teeth with a nose cone being used to maintain 
anesthesia.  The mouth was opened and the tongue was gently pulled out and to the 
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side of the mouth. A laryngoscope was then positioned to depress the tongue and see 
the cords at the top of the trachea and 50 uL of solution was administered at the top of 
the trachea.  The tongue was withheld for 3 breaths at which time the mouse was 
maintained under anesthesia for an additional 3 minutes on the dosing board. The 
mouse was then removed from the dosing board and held vertically until she began to 
recover from the anesthesia.  
3.3 Results 
3.3.1 Peptide Conjugation Efficiency. Before any of the SAgAs were injected into 
animals, the amount of peptide per SAgA was confirmed. For the first EAE study 
exploring the dosing schedule, amount and volume, approximately 9 LABL molecules 
and 8 PLP molecules were in SAgAs. Table 3.1 reports the characteristics of SAgAs that 
were used for the remaining two routes of administration studies. Using these data, a 
200-nMol PLP dose was calculated for each SAgA treatment. The average molecular 
weight of the SAgA, the approximate number of PLP and LABL molecules on one 16 
kDa HA chain, and the final ratio of PLP:LABL in SAgA were calculated using reverse 
phase HPLC data. (Table 3.1) 
3.3.2 DLS. Figure 3.1 shows the hydrodynamic radius of SAgAs ranged between 3 – 10 
nm. At concentrations at 1 mg/mL and lower, SAgA size ranged between 5 – 10 nm. 
SAgAs were injected at a maximum of 10 mg/mL, which falls in the size range of 3 – 10 
nm. A range of sizes was expected for SAgAs since the starting HA exhibits a size 
distribution and the number of peptides associated with each HA strand may vary. 
According to studies tracking passive tissue drainage of HA, SAgAs at the higher end of 
the size distribution (~10 nm) would be expected to infiltrate the lymphatic system. At the 
lower size range (~3-5 nm), SAgAs would be more likely to enter the systemic 
circulation. The size of SAgAs is also small enough to bind immune cells and be actively 
transported to secondary lymphoid organs.  
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3.3.3 EAE Study of Dosing Schedule, Amount, and Volume. The SAgA dosing 
schedule has been determined from work by Siahaan et al. using their bifunctional 
peptide inhibitor (BPI), which is a small molecule version of SAgAs that contains PLP 
and LABL with a linker in between. BPI ameliorated disease best when given on days 4, 
7, and 10, at a concentration of 100 nMol15-18. In early studies, SAgAs were injected on a 
100-nMol PLP basis, but after a small dosing study, it was found that a 200-nMol PLP 
basis decreased clinical scores of EAE mice more than the 100-nMol dose11,14. 
 Here, the treatment schedule was changed to a single SC injection on only one 
of the three treatment days (day 4, 7, or 10 of the study). Treating only on day 7 seemed 
to decrease the disease symptoms the most when compared to either the PBS-treated 
group or the group that received treatment on all three days. Differences in clinical 
score, however, were not significantly different (Figure 3.2A). The incidence of disease 
graph is another way to view the clinical scoring of animals. A score of 1.5 indicates that 
the animal experiences full paralysis of the tail with partial paralysis of hind-limbs. As a 
result, 1.5 is a critical score to determine if the disease affects mouse movement or not. 
The incidence of disease for variation of dosing schedule (Figure 3.2B) indicated, 
however, that only half of the group dosed on day 7 had a score of 1.5 or higher. 
 In another study, the dose was decreased from 200 nMol PLP to 50 nMol PLP. 
As mentioned above, the SAgA dose was calculated based on the amount of conjugated 
PLP antigen administered. Decreasing the dose reduced efficacy, even if the SC 
treatment was dosed on all three days. The clinical scores (Figure 3.2C) and incidence 
of disease (Figure 3.2D) resembled that of the PBS control group more closely than the 
group that was treated at the 200-nMol dose on all three days. 
 Lastly, the total volume of the SC injection was reduced from 100 µL to 20 µL, 
while maintaining the 200-nMol PLP dose. The clinical score data (Figure 3.2E) showed 
no difference compared to either of the control groups (PBS or SAgA treatment using 
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100 µL injections). The incidence of disease (Figure 3.2F), however, suggested lowering 
the injection volume reduced efficacy in a majority of the animals, even when the dose 
injected did not change. The significant difference in clinical scores between the 20 µL 
and the 100 µL injection suggested a larger injection volume may improve SAgA 
exposure (e.g. local drainage or systemic absorption).  
3.3.4 EAE Study of Routes of Administration. Next, the 200-nMol dose in 100 µL was 
injected into different sires: upper SC (as before), lower SC, upper IM, lower IM, and IP 
(Figure 3.3). In exploring the different routes of administration, each of the treatments 
was found to be statistically significant (p<0.05) from the PBS control group during the 
peak of disease, days 12-17 (Figure 3.4A). In this study, no difference was apparent 
between different SAgA routes of administration. Both the clinical score data and the 
weights of the animals revealed differences between the PBS control group and the 
various treatment groups. The incidence of disease graph (Figure 3.4B), however, 
suggested the upper IM group had the lowest number of animals with a disease score of 
1 or higher.  
 A subsequent study compared upper SC, IV, and PI routes of administration. The 
SC and IV group scores (Figure 3.4C) and weights (Supplemental Figure 3.2E) were 
similar to one another and were, once again, significantly improved compared to the 
PBS group (p<0.05) during the peak of disease. The PI group maintained a clinical score 
of zero and showed the best maintenance of weight throughout the study. In the 
incidence of disease profiles (Figure 3.4D), no mice in the PI group had a clinical score 
of one or higher, further supporting pulmonary instillation of SAgAs provided the best 
amelioration of disease. 
3.4 Discussion 
 In vaccine treatments, IM injections are usually given to produce an immune 
response. In contrast, SC injections are typically used for hyposensitization of patients 
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(e.g. allergy shots). Subcutaneous injections are more likely to diffuse from the injection 
site, where as intramuscular injections may form a depot, depending on the properties of 
the injected material. Since transport to the lymph nodes was thought to be vital for 
SAgAs, the SC route was chosen as it allows for both active transport and passive 
diffusion to the lymph nodes. Bagby et al. have found that injecting HA subcutaneously 
in a mouse footpad results in HA draining to lymph nodes13. Since SAgAs contain HA 
and are delivered subcutaneously, it is possible that they can also be transported to the 
lymph nodes, either by passively draining with interstitial fluid or by active transport by 
binding immune cells. Additionally, SC injection of SAgA was previously shown to 
decrease EAE scores, so dose schedule, amount, and volume were explored by this 
route first11,14. 
3.4.1 EAE Study of Dosing Schedule, Amount, and Volume. Treating on one of the 
three treatment days or injecting SAgA at a lower concentration generally caused the 
disease symptoms to increase compared to treating on days 4, 7, and 10 with 200 nMol 
PLP conjugated to SAgA. Treatment on day 4 did not allow for the disease to fully 
manifest, since 7 – 10 days are required for the immune response to occur19. Treatment 
on day 10 allowed for the symptoms to be apparent, which means that the immune 
system has already damaged the CNS (e.g., spinal cord). The incidence of disease 
graph having clinical score greater than 1.5 supports the argument that day 7 had the 
lowest incidence of disease, however clinical scores were similar for all days.  
 Arguably, day 10 would be the most similar to a clinical setting with a human 
subject. While considering the incidence of disease trends, administering treatment after 
symptoms have persisted for a few days seems not as effective as treating earlier. For 
full effectiveness, it may be important to treat before the symptoms are felt, with enough 
time for the body to process an immunological response. For example, natalizumab 
treatment regimen is given on a monthly schedule, prior to symptom presentation, which 
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would be similar to early treatment using SAgA20-23. These similar mechanisms suggest 
SAgAs may be interacting with immune cells and somehow inhibiting trafficking, 
sequestering these cells in lymphoid tissue, or triggering anergy. 
 SAgAs were not as effective when the overall dose was decreased from 200 
nMol to 50 nMol PLP. All six of the mice had a clinical score greater than 1.5 just one 
day after the PBS-treated group reached that level. While the onset of disease was 
slightly delayed, symptoms progressed very quickly once present. Going forward, a 200-
nMol PLP dose was deemed necessary for SC delivery to be effective.  
 To test the last dosing variable, SAgA concentration was increased to deliver 200 
nMol of PLP in 20 µL instead of 100 µL. The injected material was hypothesized to 
remain more local and not spread under the skin to the same extent as in the typical 100 
µL injection groups. While the onset of disease was delayed, the majority of the animals 
did get sick. The smaller volume injected did decrease the clinical score, but it was not 
as effective as the larger volume injection even though the dose was the same. In 
conclusion, the 100 µL SC injection of SAgA allowed for better amelioration of disease 
perhaps because of improved local distribution and exposure, compared to the lower 
volume injection. The larger volume injection was observed to spread under the skin to a 
greater extent than the smaller volume injection. As a result, the injection is much more 
likely to spread itself over a large surface area, giving SAgAs an increased likelihood of 
absorption or binding to peripheral immune cells for active transport. It is reasonable to 
suspect the higher volume injection may have even hydrostatically perfused more SAgA 
into lymphatic ducts, since lymph node clearance is driven by a pressure differential 
between the lymphatic ducts and tissue space. 
3.4.2 EAE Study of Route of Administration. Since changes in dose and injection 
volume changed response, the route of administration was hypothesized to have an 
important effect. EAE mice were treated using the most effective regimen (200 nMol 
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PLP, 100 µL injection days 4, 7, 10) by injecting upper SC, lower SC, upper IM, lower 
IM, or IP. All of the routes of administration significantly improved the disease state 
compared to the PBS group, but the treatment groups did not differ from each other 
(Figure 3.4A). Comparing the severity of disease in individual animals showed no 
animals in the upper IM group had a disease score of 1.5 or higher, whereas 5 out of 6 
animals in the upper SC group had a score of 1.5 or higher at the peak of disease 
(Figure 3.4B). Additionally, all of the mice in the PBS control group had a score of 1.5 or 
higher by day 13.  
 SAgAs were originally designed to transport to the lymph nodes, through either 
passive drainage or active transport. Passive drainage allows SAgAs to diffuse with 
interstitial fluid to the lymph vessels, then drain to the appropriate lymph nodes. During 
active transport, peripheral antigen presenting cells such as macrophages or dendritic 
cells may carry SAgAs to the lymph nodes (e.g., after recognizing PLP antigen24). 
Intravenous delivery of SAgAs was used to compare results from upper and lower SC, 
upper and lower IM, and IP injections. Similar efficacy via different routes of 
administration chosen for this study would suggest SAgAs may act systemically to 
ameliorate EAE. This is supported by DLS data that indicates the size distribution of 
SAgAs would include some SAgA molecules that may be small enough to enter the 
circulation and some SAgA molecules large enough to favor passive drainage via the 
lymph vessels.  
 IV administration using the same SAgA dose injection volume and schedule was 
compared to upper SC administration. The IV route provided similar disease 
amelioration and this group provided a key benchmark for comparing other routes of 
administration (Figure 3.4C). Since there was no difference in scores between the IV 
and the SC groups, it is probable that the SC injection is also delivering SAgAs 
systemically. Small, twenty-gram mice were injected with 100 µL, perhaps increasing the 
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likelihood that SAgAs absorb into circulation instead of creating a depot. In the incidence 
of disease graph (Figure 3.4D), the SC and IV treatment groups both had over half of 
the mice that were affected by the disease. This complements the clinical score data for 
the SC and IV treatment groups, supporting the notion that subcutaneous injection may 
lead to systemic delivery of SAgA. SAgAs may transport to the spleen when delivered 
systemically, which may allow for the SAgAs to interact with B and T cells. Further 
studies would be needed to support or disprove this hypothesis. 
 Finally, another route of administration was explored in this study, pulmonary 
instillation. In the ‘Hub and Spoke’ model of the immune system, T cells are licensed in 
the lung before they are distributed throughout the body25. In the case of multiple 
sclerosis, the lung is the hub and the CNS tissue is the spoke. Odoardi et al also 
determined that T cells acquire the properties needed to migrate to other parts of the 
body in the lung4. Delivering SAgAs to the lungs may allow multiple sclerosis-specific T 
cells to interact with SAgAs. An exact mechanism between T cells and SAgAs is still 
being explored, but delivering SAgAs to the lungs proved to significantly decrease EAE 
disease symptoms. After PI of SAgAs, mice showed disease scores of zero throughout 
the course of the 25-day study. In comparison to other routes of delivery (e.g., SC and 
IV), pulmonary delivery provided the lowest clinical scores, the best maintenance of 
weight, and no animals were affected by disease (Figures 3.4C and 3.4D).  
 The increased efficacy of PI of SAgAs compared to subcutaneous or intravenous 
injection may also be explained by some of the physiological differences in transport. 
Several different transport processes may occur after PI. Passive transport routes 
include diffusion of SAgAs through the lung epithelial tissue, followed by absorption into 
the lymphatic network or into circulation. Xie et al, determined that pulmonary instillation 
of an HA conjugate allowed the majority of the drug to stay within the lung, where it 
could be targeting the surrounding lymph nodes26. It is possible that the effect of SAgAs 
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after PI administration is more pronounced than SC or IM because of the shorter 
pathways from the lung to the lymph node, thus leading to higher dose or better timing 
during the pre-symptomatic stage of immune response.  
 Another possibility to consider is that SAgA degradation and diffusion of 
components is possible, but our previous studies have shown neither free peptides nor 
HA (alone or in combination) have a therapeutic effect11. Active processes of mucocillary 
clearance and macrophage clearance may also affect SAgA transport. Mucous is 
transported by cilia located in the conducting airways and is deposited in the oropharynx 
and swallowed. The potency of SAgAs administered PI suggest minimal mucociliary 
clearance. Macrophage clearance typically occurs in the lower airways including terminal 
bronchioles and alveoli. Macrophages then transport phagocytosed cargo to the lymph 
nodes for processing. Lymph nodes are key to the efficacy of immune therapies, since 
that is a primary site of immune cell priming. 
 Observations from SC and IV routes of administration do not support a systemic 
mechanism of SAgA efficacy of after PI. Although, it is possible increased PI efficacy is 
linked to avoiding fist pass metabolism, which could diminish SAgA effect after IV or SC 
administration. Furthermore, it is plausible the lung may act as a SAgA depot after PI, 
since macrophage clearance can take days, providing an extended duration of action 
compared to the other administration routes. Perhaps the most plausible explanation is 
that pulmonary instillation may offer a direct avenue to the lymphatic system, either 
passively or via active transport or may somehow bind and inhibit T cells migrating 
through the lungs to be licensed for trafficking to the CNS. Additional studies will be 
required to elucidate these possible mechanisms. 
3.5 Conclusion 
 SAgA treatment schedule, dose, injection volume, and routes of administration 
were systemically explored to treat EAE. Timing the SAgAs dose was important, 
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suggesting it must follow the schedule of a typical natalizumab dosing, before symptoms 
are fully realized. Decreasing SAgA dose to 50 nMol (i.e. 50 nMol of PLP delivered) 
administered on days 4, 7, 10 was not as effective as 200 nMol. Decreasing the volume 
of the dose to 20 µL meant increasing the concentration 5 fold and SAgAs were slightly 
less efficacious at the lower volume, suggesting the lower volume, higher concentration 
had limited exposure.  
 Exploring routes of administration provided new insight into possible mechanisms 
of action. The initial goal was to deliver SAgAs to lymph nodes. The first set of 
administration sites (upper and lower SC, upper and lower IM, and IP) was chosen with 
this goal in mind. Previous studies suggested a portion of SAgAs injected at the upper 
SC site would drain to the cervical lymph nodes, which drain the CNS and are implicated 
in EAE. Delivering SAgAs via the SC route was similar to delivering IV suggesting all 
peripheral injections may be acting via systemic exposure. The most surprising result 
was that the pulmonary delivery of SAgAs decreased the clinical scores with no mice 
exhibiting symptoms throughout the study. Applying the ‘Hub and Spoke’ theory to 
pulmonary delivery, it is possible that delivering SAgAs to the lungs allows maximized 
interaction with the immune system, either within the lung or via local lymphatics. 
 To further explore mechanisms of SAgA efficacy, the dosing schedule, amount, 
and volume studies could be repeated via the pulmonary instillation route of 
administration. Further studies that track the distribution of SAgA throughout the mouse 
after pulmonary instillation would provide useful insight to the trafficking of SAgA 
molecules. Additionally, in vitro work is under way to determine target cells by screening 
SAgAs in EAE splenocytes and measuring cytokine responses to help explain the 
efficacy observed in EAE mice. 
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Table 3.1. Using pH 1.0 solution, the peptides were hydrolyzed from HA to indirectly 
quantify the amount of AoPLP (circle) and AoLABL (triangle) grafted to SAgA. 
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Figure 3.1. DLS measurements show various concentrations of SAgAs to measure 
between 3 – 10 nm in hydrodynamic radius.  
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Figure 3.2. Clinical score and incidence of disease data for dosing schedule, dosing 
amount and dosing volume. For the incidence of disease data, a disease score of 1.5 or 
higher shows that the animal is affected by the disease.  (A) Dosing schedule was 
changed to one of the three treatment days. There is significance (p<0.05) on Days 13 
and 15 of the study between the PBS control group and the group that was treated only 
on Day 7. (B) The incidence of disease for the dosing schedule study shows that treating 
on Day 7 results in the lowest incidence of disease. (C) Dosing amount clinical scores 
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indicated that decreasing the dose decreases the effectiveness of the treatment. (D) The 
incidence of disease for the dosing amount study showed that decreasing the dose 
increased the number of animals affected by the disease. (E) The dosing volume clinical 
scores showed that the lower volume injection is not as effective in comparison to the 
100 uL injection. (F) The incidence of disease for dosing volume shows that the lower 
injection volume had a 50% greater incidence of disease. 
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Figure 3.3. Injection sites for route of administration studies.  
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Figure 3.4. Route of administration study clinical score (A) and incidence of disease (B) 
data. (A) There is no difference between different routes of administration, but there is a 
significant difference (p<0.05) between the PBS-treated group and all other SAgA-
treated groups on Days 12-18. (B) Incidence of disease plots show animals with a 
disease score of at least 1.5 affected by the disease. The upper IM group was the least 
affected and the PBS-treated and upper SC groups were the most affected. (C) The 
pulmonary instillation group had disease scores of 0 throughout the peak of disease. (D) 
No animals in the pulmonary instillation group had a score of 1.5 or higher. 
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Chapter 4: 
Pulmonary Administration of Soluble Antigen 
Arrays (SAgAs) is Superior to Antigen in 
Treatment of Experimental Autoimmune 
Encephalomyelitis  
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4.1 Introduction 
 Inducing antigen specific immune tolerance is an emerging avenue of treatment 
of autoimmune diseases1.  The classical approach of antigen specific immunotherapy 
(ASIT) has been to desensitize the immune system through a series of subcutaneous 
injections.  This approach has generally been applied to foreign antigens (e.g., 
hyposensitization in the form of “allergy shots”).  The treatment regimen, however, 
requires injections over multiple years and disease improvement is often modest1-5.  
Similar strategies have been investigated for desensitizing patients to autoantigens 
including proinsulin peptide for type-1 diabetes6, splicesomal peptide for Lupus7, and a 
pathogenic peptide for rheumatoid arthritis8.  Alternative delivery approaches have 
appeared as strategies to improve efficacy of ASIT.  Recently, new products including 
Ragwitek® and Grastek® utilize sublingual administration to desensitize the immune 
system to foreign antigens through mucosal surfaces.  Treating mucosal surfaces, such 
as nasal passages or lungs, may also improve performance or reduce the timeline 
required for ASIT, a concept that may also extrapolate to autoimmune diseases2,5,9.  
 Traditional ASIT induces tolerance of allergens over the course of treatment. As 
a result, the immune system is slowly desensitized, avoiding an immune response 
against said antigen. Because the immune system cannot differentiate between self and 
non-self in autoimmune diseases, an autoimmune response occurs. Thus, it may be 
possible to apply ASIT approaches to educate the immune system to tolerate the self-
antigen associated with autoimmune diseases. One particular autoimmune disease this 
concept has been applied to is Multiple Sclerosis. 
Multiple Sclerosis (MS) is an autoimmune disease, where immune cells attack 
and degrade the myelin sheath surrounding neurons, thus interrupting the transmission 
of electrical signals3,4,10,11.  Many of the current therapies approved for MS focus on 
treating inflammation or neurological symptoms such as loss of balance, degrees of 
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paralysis, and a loss of coordination.  Recently, researchers have aimed to correct the 
underlying immune response using ASIT.  If this autoimmunity is uncorrected, patients 
can experience progressive cycles of remission and relapse, where periodic symptoms 
are followed by remission, but the patient does not fully recover to the previous baseline.  
There are different forms of this disease: secondary progressive, primary progressive, 
progressive relapsing, and relapsing remitting, which affects a majority of patients, 
approximately 80%4,10,11. Experimental autoimmune encephalomyelitis (EAE), the murine 
model of relapsing and remitting MS, is induced by a proteolipid protein epitope (PLP139-
151) and serves as a useful model for studying ASIT approaches to autoimmune 
diseases3,4,12. 
We explored ASIT using pulmonary delivery of multivalent soluble antigen arrays 
(SAgAs), which are composed of a hyaluronic acid (HA) polymer backbone with grafted 
myelin sheath epitope PLP139-151, and a grafted peptide inhibitor (LABL) of cell surface 
receptor intracellular cell-adhesion molecule-1 (ICAM-1)3.  Previous work has shown that 
pulmonary delivery of SAgAs had increased efficacy compared to subcutaneous and 
intravenous delivery4. In this chapter, SAgAs, its components (HA, LABL, and PLP), and 
a bifunctional peptide inhibitor (BPI) containing LABL and PLP were compared when 
delivered to the lungs of mice. Clinical scores and cytokine responses were compared to 
elucidate mechanisms of inducing immune tolerance in mice with EAE. 
4.2 Materials and methods 
4.2.1 Materials 
Hyaluronic acid (HA) molecular weight 16 kDa was purchased from Lifecore 
Biomedical (Chaska, Minnesota).  Aminooxy-LABL (AoLABL) and Aminooxy-PLP 
(AoPLP) peptides were obtained from PolyPeptide, Inc. (San Diego, CA).  Incomplete 
Freund’s Adjuvant Oil and Mycobacterium tuberculosis were obtained from BD Difco 
Adjuvants (Franklin Lakes, New Jersey) and pertussis toxin was purchased from List 
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Biological Laboratories, Inc. (Campbell, California).  The mouse laryngoscope was 
purchased from Penn-Century (Wyndmoor, Pennsylvania).  All water used was 
deionized (DI) water from a Labconco Pro PS system.  All other chemicals and materials 
including 3500 Da molecular weight cutoff dialysis tubing, bent fine dissecting forceps, 
glacial acetic acid, sodium acetate, sodium phosphate monobasic monohydrate, sodium 
phosphate dibasic, and phosphate buffered saline were purchased from Fisher Scientific 
(Pittsburgh, Pennsylvania). 
4.2.2 Soluble Antigen Array (SAgA) Synthesis  
The purified peptides were conjugated onto HA.  In 20-mM acetate buffer pH 5.5, 
a concentration of 2 mg/mL of 16.9-kDa HA was made.  AoLABL and AoPLP peptides 
were added in equal molar proportions, then were added to the 2-mg/mL HA solution 
using a ratio of 2 HA monomers to 1 Ao peptide.  The reaction was allowed to proceed 
for 24 hours at room temperature.  After 24 hours, the reaction mixture was added to 
3500-Da molecular weight cutoff dialysis tubing using DI water as the dialysate for 24 
hours with the dialysate being changed every 6 hours.  Samples were then frozen and 
lyophilized for 72 hours at a condenser temperature of -72 °C and at a vacuum of <300 
millitorr (VirTis Feezemobile-12XL, The Virtis Company, NY). 
The peptide loading of SAgAs was analyzed using reverse phase high 
performance liquid chromatography (RP-HPLC) and size exclusion chromatography 
(SEC).  SAgAs were dissolved in 0.1-M HCl pH 1.0 for 4 hours to hydrolyze peptides 
from the HA backbone.  With the HPLC, a calibration curve of free peptide was 
employed to determine the amount of peptide that was conjugated to the HA for SAgAs, 
which was compared to the relative size ascertained from SEC.  The HPLC analysis was 
performed using a Waters 2487 dual absorbance detector and a Waters 2796 
bioseparation module.  A gradient separation was performed with a mobile phase A 
comprised of 94.9% DI water, 5% acetonitrile, and 0.1% trifluoroacetic acid and mobile 
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phase B comprised of 99.9% acetonitrile and 0.1% trifluoroacetic acid.  The gradient was 
100% A from 0 to 15 minutes, 85% A at 15 minutes, 83% A at 20 minutes, 80% A at 33 
minutes, 75% A at 42 minutes, 30% A at 43 minutes, and 100% A at 46 minutes until 60 
minutes with a total flow rate of 1 mL/min.  A C18 Higgins Analytical Proto200, 5 µm, 200 
Å, 250 × 4.6 mm2 column was used with an injection volume of 30 µL using samples with 
a concentration of 1 mg/mL with wavelength detection at 220 nm.     
SEC was employed to determine the increase in size of SAgA from HA due to 
the conjugation of peptides to HA.  The system used included a Waters e2695 
separation module, Waters 2414 refractive index detector, and Waters 2489 UV/Vis 
detector with two columns in series: a PL Aquagel-OH 60 Analytical SEC (300 x 7.5 mm) 
then a PL Aquagel-OH 40 Analytical SEC (300 x 7.5 mm).  The mobile phase employed 
for SEC was of 0.1-M ammonium acetate with 0.136M sodium chloride at pH 5 using an 
isocratic system.  Samples injected were 80 µL at a concentration of 5 mg/mL with a 
total flow rate of 0.5 mL/min flow.  Samples were dissolved in the mobile phase at a 
concentration of 5 mg/ml and chromatograms were analyzed using EMPower 3. 
The hydrodynamic radius of the samples was determined using ZetaPALS. The 
samples were all at a concentration of 1 mg/mL and then dissolved in filtered phosphate 
buffered saline (PBS). Each of the samples was filtered once again immediately before 
the readings were taken. Three readings were taken per sample and then averaged for 
the values seen in the results (Table 4.1). 
4.2.3 Animals 
SJL/J mice (female, 4 weeks old) were supplied by Harlan Laboratories 
(Indianapolis, IN) for the study.  Mice were approximately 13-16 g and were weighed 
throughout the course of the experiment.  The mice were housed in a pathogen-free 
facility at the University of Kansas approved by the Association for Assessment and 
Accreditation of Laboratory Animal Care (AAALAC).  Mice were maintained on a 12 hour 
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light/dark cycle and were fed standard rodent pellets with no dietary restrictions or 
withheld food and water was always available.  All animal experiments were approved 
by the University of Kansas Institutional Animal Care and Use Committee (IACUC). 
4.2.4 Induction of Experimental Autoimmune Encephalomyelitis (EAE) and Time 
Course of Study 
 Each SJL/J mouse had EAE induced on study day 0 with 4 injections of an 
emulsion of Incomplete Freund’s Adjuvant Oil, Mycobacterium tuberculosis, and 200 nM 
of PLP.  Each of the 4 injections was 50 µL given subcutaneously: 2 above the shoulder 
blades and 2 above the rear hip haunches.  Each SJL/J mouse had 100 µL of 200 ng 
pertussis toxin injected intraperitoneal on day 0 as well as day 2.  There were 6 mice in 
each of the groups split into 2 cages of 3 mice. 
 Over the course of the 25-day study, each mouse was weighed and given a 
clinical score from study day 7 to 25.  The clinical scoring ranged from 0 to 5 with half 
integer values and a higher score correlated to an increase in disease progression.  The 
advancement of the scoring was as follows: 0 corresponded to no symptoms of disease; 
1 with a limp tail and waddling gait; 2 with partial leg paralysis and increased alteration of 
gait; 3 with paraplegia or complete hind leg paralysis; 4 with partial front leg paralysis; 
and 5 with complete front leg paralysis or moribund.  Half integer values corresponded 
with disease between scoring levels3,4. 
4.2.5 Treatment Schedule and Pulmonary Instillation of Compounds  
 Treatment was administered on study days 4, 7, and 10.  Before treatment, each 
of the study compounds was dissolved in sterile PBS. The study groups were PBS, 16 
kDa HA, LABL, PLP, SAgA, and bifunctional peptide inhibitor (BPI).  Each animal was 
administered 50 µL of each compound corresponding to 200 nM with the exception of 
BPI, which was 150 nM administered via pulmonary instillation as described in details 
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below3,4.  All the statistical analyses were performed on Prism GraphPad 5 software 
using ANOVA analysis. Tukey post-hoc analysis was applied to the data. 
For lung administration via pulmonary instillation, each animal was anesthetized 
with 2% isoflurane in oxygen in an induction chamber for approximately 4 minutes.  After 
the mouse was fully anesthetized, the mouse was positioned in dorsal recumbency 
using a dosing board at approximately 60° to a supine position suspended by incisor 
teeth using a thin wire.  A nose cone was used to maintain anesthesia.  The mouth was 
opened and the tongue was gently pulled out and to the side of the mouth.  A 
laryngoscope was then positioned to depress the tongue and visualize the vocal cords at 
the top of the trachea.  A 50 µL solution of HA was then pipetted at the top of the 
trachea.  The tongue was withheld for at least 3 breaths, after which time the mouse was 
maintained under anesthesia for an additional 3 minutes on the dosing board.  The 
mouse was then removed from the dosing board and allowed to recover from the 
anesthesia by being held vertically until movement was regained13. 
4.2.6 Collection and Culturing of Splenocytes 
The mice were euthanized via isoflurane overdose. Spleens were harvested 
under sterile conditions and were immediately transferred to a Falcon tube with 5 mL 
sterile RPMI media with 1% Penicillin-Streptomycin (P/S). Within 30 minutes, the 
spleens were mashed under sterile conditions using a wire mesh in a petri dish and the 
rubber stopper of a 1-mL syringe plunger. A 5-mL pipette was used to transfer the cell 
solution to a 15-mL Falcon tube. The splenocytes were centrifuged at 3500 rpm for 4.5 
minutes. The old media was decanted and the cells were resuspended in 1 mL of RPMI 
with 10% fetal bovine serum (FBS) and 1% Penicillin/Streptomycin.  
 A fresh solution of Gey’s Lysis solution was made and 3.5 mL was added to the 
splenocytes. The cells were set on ice for 3.5 minutes to lyse the red blood cells. Then, 
10 mL RPMI with 10% FBS and 1% P/S was added to the cells. They were centrifuged 
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once again at 3500 rpm for 4.5 minutes. The media was decanted and the cells were 
resuspended in 5 mL of fresh RPMI with 10% FBS and 1% P/S. The cells were counted 
using a hemocytometer and were plated at 5 x 106 cells per well at 500 µL per well in a 
24-well plate. The splenocytes were incubated for 120 hours before the supernatant 
containing cytokines was collected and resazurin assay was conducted.  
4.2.7 Determination of Cytokine Profiles by ELISA 
ELISAs from R and D Systems (Minneapolis, MN) were used to determine the 
following cytokine levels (IFN-γ, TNF-α, IL-2, IL-6, IL-10, and IL-17).  A 100-µL aliquot of 
the collected supernatant was used for each of the ELISAs except for IFN-γ and IL-17, 
where the samples were diluted 2:5 using RPMI media with 10% FBS and 1% P/S. The 
ELISA was read using a SpectraMax plate reader at an absorbance of 450 nm. The 
protocol for each of the ELISAs was provided by R and D Systems. 
4.2.8 Lung Histology 
Mice were euthanized as described previously.  An incision was made in the 
ribcage to expose the trachea and lungs.  A 10% formalin solution was injected into the 
trachea down into the lungs via a syringe until inflation was observed via visual 
inspection, which typically required 3 mL.  The lungs were tied off using nylon sutures to 
keep the lungs inflated with 10% formalin and were suspended in 10% formalin in a 50 
mL test tube.  Enough formalin was used to cover the lungs and the test tube was 
inverted to maintain the lungs in formalin.  After 24 hours, the remaining tissue was 
removed from the lungs, leaving just the lungs, which were then split into right and left 
and were placed in a histology cassette in 70% ethanol.  After 72 hours, the 70% ethanol 
was replaced to remove excess red blood cells from solution. 
For histology, the mice lungs were sectioned and submitted for formalin fixation. 
Briefly, the specimens were grossed and submitted in plastic cassettes. The cassettes 
then underwent additional processing within a Tissue-tek VIP Tissue Processor, at a 
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temperature of 10° - 40° C. The tissue went through further formalin fixation followed by 
70% alcohol, 95% alcohol, 100% alcohol, and xylene. The tissue was then embedded in 
paraffin wax at 62° C. 
The paraffin embedded tissue was then sectioned with a microtome at four 
microns per section. These slides containing both the paraffin and tissue were then 
placed into an oven to remove excess paraffin wax. After the slides and tissue were 
cooled, they were stained with hematoxylin and eosin. A cover slip was placed over the 
stained tissue samples allowing the tissue to be evaluated. 
4.3 Results  
4.3.1 Characterization of SAgAs 
 Reverse phase chromatography was utilized to determine the amount of peptide 
conjugated to HA.  Based on the RP-HPLC results, there were approximately 5 to 6 PLP 
peptides and 7 to 8 LABL peptides conjugated per polymer chain.  By determining the 
number of peptides conjugated, the approximate average molecular weight was 
calculated using both SEC and HPLC results (Table 4.1). The ZetaPALS readings for 
hydrodynamic radius are also reported in Table 4.1. 
4.3.2 Co-Delivery of Peptides Offers Improved Therapeutic Efficacy 
 The co-delivery of peptides using SAgAs was necessary for ameliorating EAE 
symptoms.  The mice were treated on study days 4, 7, and 10, as was previously 
established in earlier publications.  The PBS group had high clinical scores that were 
similar to the group treated with LABL (Figure 4.1).  Both groups had scores that 
increased as of day 10 with the PBS group having the highest scores between days 12-
15 and peaking on 14, while LABL peaked slightly earlier at day 12.  Scores for mice 
administered PBS or LABL remained high throughout the course of the study, ending 
with scores of approximately 1.0.  The HA group had a slightly delayed onset of disease 
as disease was observed at day 11, peaking on day 14, and decreasing to near baseline 
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values by day 18.  The PLP group had similar scoring to the BPI group with scores 
remaining around 0.5 after disease onset.  The SAgA group had low scores throughout 
the length of the study with scoring ranging between approximately 0 and 0.25, but were 
not statistically different from PLP and BPI. 
 The area under the curve (AUC) from clinical scores in Figure 4.1 provides a 
holistic view of the disease state of EAE mice (Figure 4.2).  The PBS group had the 
highest AUC of approximately 20 with LABL being similar.  HA showed a decreased 
AUC compared to LABL and PBS but was higher compared to both PLP and BPI 
treatments.  BPI and PLP were quite similar, while SAgA had the lowest AUC value, 
although not statistically lower than the BPI treatment. 
 The incidence of disease was also determined (Figure 4.3).  Mice are 
considered ‘diseased’ when progressing to a score of 1.0 or higher, corresponding to 
symptoms affecting the rear legs as well as the tail.  The PBS, HA, and LABL groups 
had a rapid progression to disease. All HA and PBS-treated animals were sick by day 14 
and all LABL-treated animals by day 17.  The PLP group had only 1 animal remain 
disease free throughout the course of the study.  The BPI group had 4 of 6 animals 
remain disease free, while the SAgA group had 5 of the 6 animals remain disease free.   
Changes in the weights of animals were also assessed throughout the study 
(Figure 4.4).  The weight of the animal decreases around the onset of disease due to 
decreased mobility of the animal and general decrease of health.  Typically, animal 
weight begins to decrease around day 10 and as the disease resolves, weight will 
gradually increase.  The PBS, LABL, and HA groups had similar decreases in weight 
starting on day 10 with the greatest decrease in weight occurring on days 14 and 15, 
corresponding to peak of disease.  All three groups had similar weights by the end of the 
study, recovering to levels similar to the starting weights.  The BPI and PLP groups, 
again, were quite similar with decreases in weight from day 11 to 18 but with less weight 
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loss compared to PBS, HA, and LABL groups.  The SAgA group had almost continuous 
weight gain throughout the course of the study ending with ~10% weight gain on 
average. 
4.3.3 Cytokine Profiles from Splenocytes 
 Splenocytes were harvested from treated and control animals at the end of the 
study. Splenocytes were exposed to media with or without PLP and the cytokine 
response was determined. IFN-γ levels were significantly higher in splenocytes derived 
from animals treated with SAgAs compared to animals that were dosed with the 
individual components (Figure 4.5).  IL-6 and IL-17 levels were significantly higher in 
splenocytes from animals treated with SAgAs compared to animals that received only 
PLP antigen. IL-2 levels were lower in animals treated with PLP, SAgA, and BPI 
compared to animals dosed with PBS, HA, or LABL. IL-10 and TNF-α levels in the SAgA 
and BPI groups trended slightly higher than other groups, but there was no statistical 
significance. 
4.3.4 Lung Histology  
 Lung histology highlighted some intriguing trends but it was difficult to draw firm 
conclusions based on the heterogeneity of the results within and between groups 
(Figures 4.6 and 4.7).  Inflammation from the lungs was scored by differentiating into 
three distinct categories of mild, moderate, and severe inflammation, as described in 
Zhornitsky et al14.  The treatment groups of PBS, LABL, and HA had a wide range of 
scoring with animals ranging from no inflammation (0) and mild focal inflammation (1) to 
severe diffuse inflammation with granulomas (6).  Due to the wide range of scores, a 
quantitative analysis showed no statistical difference (Figure 4.7).  The treatment groups 
of SAgA and BPI had lower cumulative scores across the groups with maximum lung 
inflammation of 2 still qualifying as mild.  The remaining group of PLP was more similar 
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to the SAgA and BPI groups with a lower average and with most of the animals having 0 
or 1.  
4.4 Discussion 
4.4.1 The Lungs and Immune Tolerance 
 Antigen-specific immunotherapies are traditionally administered via 
subcutaneous injections.  Injections of antigens can potentially transport by two 
mechanisms: (i) via diffusion from the injection site to regional lymph nodes or systemic 
circulation or (ii) via active cellular transport to lymph nodes1-5.  Mucosal delivery, 
including buccal (e.g. Grastek®), nasal, and pulmonary delivery, offers a convenient 
route of administration and recent studies have suggested the potential for improved 
tolerization compared to subcutaneous injection.  Mucosal surfaces serve as the primary 
barrier to entry and are constantly inundated with foreign pathogens.  These surfaces 
have their own mucosa-associated lymphoid tissue, which includes specialized epithelial 
cells that can take up antigens and direct the antigens to antigen presenting cells to elicit 
an immune response2,5,9,15.  More recently, however, additional immunological 
mechanisms of the lungs have emerged. 
4.4.2 The ‘Hub and Spoke’ Hypothesis of Immune Cell Licensing in the Lungs  
 Recent research has suggested the lungs may have a unique role in the immune 
system. For example, the ‘Hub and Spoke’ hypothesis suggests immune cells traffic 
through the lungs (‘hub’) acquiring information required to migrate to different parts of 
the body.  Once these immune cells are imbued with this information (‘licensed’), they 
can pass through to the particular ‘spoke’, such as the brain for MS, pancreas for type-1 
diabetes, and the large intestine for irritable bowel disease16.  In support of this, a recent 
publication showed that activated immune cells specific to CNS antigens did not elicit 
CNS symptoms until 5 days after injection when given intravenously.  If these same cells 
were delivered directly into the CNS, no symptoms were observed.  If administered 
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directly into the lungs, however, these cells elicited CNS symptoms after approximately 1 
day17,18.   
The ‘Hub and Spoke’ hypothesis appears to be especially important for T cells, 
dictating migration to a particular location in the body by modifying transcription and 
translation of integrin molecules necessary for homing to target tissues. Inhibitors of 
tissue-specific integrins have proven to be successful as therapeutics (e.g. TYSABRI®).  
Thus, interfering with immune cells during licensing in the lungs of EAE mice may be a 
viable therapeutic approach.  Researchers are currently elucidating the immune cell 
populations passing through the lungs and are tracking cells to determine how these 
cells affect disease.  Modification of the immune response may hinge on the ability of 
cells to migrate through the lungs and to tissue compartments.  Thus, the lungs provide 
an intriguing route of ASIT administration to skew immune responses throughout the 
body16-18. 
4.4.3 Potential Immune Modulation Mechanism for SAgAs 
Pulmonary delivery of SAgA components indicated the need for co-delivery of the 
PLP antigen epitope with LABL peptide to reverse EAE in mice.  HA has some inherent 
immune activity as it can bind to CD44 on immune cells yet no therapeutic efficacy was 
observed with the delivery of HA.  The delivery of LABL also did not change the disease 
state suggesting blocking ICAM-1, a known mediator of immune cell adhesion and co-
stimulation, was not therapeutic.  It is possible that it was quickly eliminated from the 
lung tissue via clearance or absorption or that LABL was digested quickly by peptidases 
in the lungs.  Treating with PLP alone had increased efficacy based on the AUC of the 
clinical scores, but most EAE mice treated with PLP became sick.  Animals treated with 
PLP had a delayed onset of disease and exhibited decreased scores compared to HA 
and LABL hinting that PLP may function as conventional ASIT.  If this is the case, 
repeated, escalating doses may hyposensitize EAE mice to PLP.  Ultimately, the co-
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delivery of the peptides practically eliminated disease as seen with both BPI and SAgA 
suggesting that efficacy depends on co-incident delivery of both PLP and LABL.   
4.4.4 Cellular and Cytokine Response in EAE with SAgA Treatment 
 Cytokine profiles provide some insight regarding possible mechanisms of action 
for SAgA therapy.  Some cytokines have been classically considered to be pro-
inflammatory or anti-inflammatory but with further study the picture becomes more 
complex.  For example, IFN-γ has traditionally been identified as a deleterious 
inflammatory response when elevated in autoimmune diseases.  New studies, however, 
have shown that local, elevated levels of IFN-γ may not always correspond to 
inflammatory responses.   
 Cytokine profiles differ kinetically throughout the course of the disease and 
spatially depending on the tissue compartment. Circulating cytokines will differ from 
cytokines gathered from splenocytes, which are also different from cytokines expressed 
in affected tissues (e.g. MS brain lesions). We observed a pronounced IFN-γ response 
in splenocytes from mice that received SAgA treatment19. Splenocytes were collected at 
day 25, during remission of EAE, thus, PLP-specific T cells may have returned to the 
spleen, which caused the spike in IFN-γ levels. In related studies, Kobayashi et al. 
reported the levels of IFN-γ seem to be significantly higher in the group of mice treated 
with PLP-BPI in comparison to the PBS group. The levels of IFN-γ were significantly 
higher in mice treated with SAgAs than that of mice treated with PBS, 16kD HA, PLP, 
and LABL. Following the trends seen with Kobayashi, it is possible that the increased 
levels of IFN-γ from splenocytes corresponded to improved treatment efficacy. 
IL-6 responses from splenocytes were also high in mice treated with SAgA. IL-6 
may cause EAE to progress, suppressing Fox3P+ Treg cells, causing a pro-
inflammatory response20. Similar to the rationale for IFN-γ, IL-6-producing cells may 
	   59	  
have returned to the spleen during remission, instead of being present in the CNS. A 
similar rationale may apply to the observed increase in IL-17. 
 The IL-2, IL-10, and TNF-α results in Figure 4.5 were not statistically different. 
IL-2 is known for differentiation of T cells, and is typically pro-inflammatory, as shown by 
Saskida, et al21, suggesting this cytokine should increase as did IFN-γ. But, no change 
was seen in these cytokines, as has been shown in literature3,19. All three cytokine 
levels, however, seem to be similar to previous studies22.  
 One major reason for the variation in cytokine levels reported in literature is 
because of comparisons made between differing time points of the study. Cytokines in 
the spleen will differ at the point before disease symptoms were prominent, at the peak 
of disease, and at the end of the study, where symptoms had decreased. Assays of 
cytokines secreted from splenocytes also use time points from 0 hours to 120 hours after 
starting the primary splenocyte culture. Future studies should compare cytokine levels in 
different tissue samples over the course of the study, as well as compare cytokines 
collected at varying time points after the primary splenocyte culture is established.  
Some of the results may be explained by looking at potential immune interactions 
of SAgAs compared to earlier studies of BPI treatment. Like SAgA, BPI is also 
composed of the PLP peptide and the LABL peptide, but with a short linker connecting 
the two peptides.  When antigen presenting cells such as dendritic cells interact with T 
cells, they form an immunological synapse where the cell surface receptors coalesce 
into a distinct pattern23,24.  It was previously shown that a BPI molecule called GAD-BPI 
with glutamic acid decarboxylate (GAD) peptide antigen could effectively colocalize both 
MHC-II and ICAM-1 on the surface of antigen presenting cells (APCs) from NOD mice 
compared to a mixture of GAD peptide and LABL peptide25.  The results suggested that 
GAD-BPI molecule could bind simultaneously to MHC-II and ICAM-1 on the surface of 
APCs. As a result, the BPI molecule prevented the aggregation of TCR/MHC-II-Ag 
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complex from LFA-1/ICAM-1 complex to form clusters for the immunological synapse at 
the interface between T cell and APC26. Blocking the formation of the immunological 
synapse can alter the differentiation of subpopulation of T cells.  
Besides possible cytokine and cellular mechanisms, transport of SAgA molecules 
may be substantially different than BPI.  Previous work on SAgAs reported a range of 
physical sizes as determined by the HA polymer size and the amount of peptide 
conjugated.  The size of SAgA constructs has typically ranged from 3-10 nm4.  This size 
range may facilitate access to different physiological compartments as the largest of 
these, 10 nm, can potentially be excluded from absorption into systemic circulation and 
passively drain to the lymphatics27-29.  It is plausible SAgA molecules reduced lesions in 
the lungs as a result of longer persistence.  Alternatively, active binding to immune cells 
and transport to secondary lymphoid organs may be a likely mechanism of SAgA 
efficacy, which could favor smaller, more mobile SAgAs or BPI. Future studies aim to 
define these potential mechanisms when comparing SAgAs to conventional ASIT. 
4.5 Conclusion 
 Restoring immune tolerance in autoimmune diseases may one day reverse the 
root cause of disease. ASIT has been used for decades to desensitize patients to 
allergens, but similar approaches applied to autoimmune diseases have yet to achieve 
robust clinical success.  Traditional allergy desensitization strategies have employed 
injections, while new approaches have achieved immune tolerance by applying ASIT to 
mucosal membranes (e.g. Grastek® and Ragwitek®), suggesting the lung may also be a 
viable target tissue.  SAgA molecules exhibiting grafted antigen and a grafted inhibitor of 
immune cell adhesion may amplify the effect of traditional ASIT.  SAgAs with grafted 
PLP and LABL delivered into the lungs of EAE mice showed increased efficacy based 
on clinical scoring, weight gain, and incidence of disease compared to the individual 
components.  The cytokine response of splenocytes indicated a shift towards increased 
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levels of IFN-γ when treated with SAgA compared to the individual components and 
elevated IL-6 and IL-17 with SAgA compared to PLP.  Cytokines, such as IL-10, IL-2, 
and TNF-α showed no significant difference and yet co-delivery of PLP and LABL using 
SAgAs or BPI provided a potent ASIT when delivered to the lungs and the distinct 
mechanisms of these therapeutics merits further exploration.  
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Table 4.1: Characterization of treatments. 
Sample Molar Ratio of LABL:PLP:HA 
Approximate 
MW (kDa) 
Dh in PBS 
(nm) 
Hyaluronic 
Acid (HA)  0:0:1 16 2.4 ± 1.0 
Proteolipid 
Protein  
(PLP139-151) 
 0:10:0 1.5 N/A 
LABL  10:0:0 1.0 N/A 
Soluble 
Antigen Array 
(SAgA)  
7.5:5.8:1 33 3.7 ± 1.6 
Bifunctional 
Peptide 
Inhibitor (BPI) 
 1:1:0 3.0 N/A 
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Figure 4.1: Clinical scores throughout the study from each of the 6 groups: PBS control, 
HA, LABL, PLP, SAgA, and BPI.  Panel A depicts all 6 groups; Panel B shows PBS, HA, 
and SAgA; Panel C represents PBS, PLP, and SAgA; and Panel D depicts PBS, LABL, 
A 
C D C D 
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and SAgA.  Each point is the average of 6 animals with the standard deviation within 
each group.   
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Figure 4.2: Area under the curve (AUC) of clinical scores throughout the study from 
each of the 6 groups.  Each group is the aggregate total of the scores from the 6 
animals. 
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Figure 4.3: Incidence of disease, represented by a clinical score of 1.0, throughout the 
study from each of the 6 groups (PBS control, HA, LABL, PLP, SAgA, and BPI).  Panel A 
depicts all 6 groups; Panel B shows PBS, HA, and SAgA; Panel C represents PBS, PLP, 
and SAgA; and Panel D depicts PBS, LABL, and SAgA.  Each point is the average of 6 
animals with the standard deviation within each group.   
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Figure 4.4: Change in weight based on normalization to the initial weight on Day 0 
throughout the study with all 6 groups (PBS control, HA, LABL, PLP, SAgA, and BPI).  
Panel A depicts all 6 groups; Panel B shows PBS, HA, and SAgA; Panel C represents 
A 
C D 
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PBS, PLP, and SAgA; and Panel D depicts PBS, LABL, and SAgA.  Each point is the 
average of 6 animals with the standard deviation within each group.   
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Figure 4.5: Cytokine profiles with IFN-γ in Panel A, IL-6 in Panel B, IL-2 in Panel C, and 
IL-10 in Panel D.  
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Figure 4.6: Histology of lungs from a mouse from each group.  Each image was taken at 
100X magnification and was performed after staining and fixing of tissue. Panel A is 
mouse 706 from the PBS group and shows severe inflammation; B is mouse 721 from 
the HA group and shows mild inflammation; C is mouse 719 from the LABL group and 
shows moderate inflammation; D is mouse 792 from the PLP group and shows 
moderate inflammation; E is mouse 725 from the SAgA group and shows no 
inflammation; F is mouse 703 from the BPI group and shows mild inflammation. 
PBS- 706 HA- 721 LABL- 719 
PLP- 792 SAgA- 725 BPI- 703 
B C 
D E F 
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Table 4.2. Lung histology descriptions and scores. H denotes histiocytes and L denotes 
lymphocytes with letter coming first being the major cell population. Scores range 
between 0 and 6, with the higher scores indicating a higher level of inflammation. 
 
 
Mouse 
Number 
Description of 
Inflammation 
Granuloma Immune 
Cells Score 
PBS 
704 
 
706 
 
 
794 
 
796 
 
797 
 
800 
Mild, focal  
 
Severe, nodular 
and diffuse 
 
No inflammation 
 
Mild  
 
Mild, focal 
 
Moderate  
No 
 
Yes 
 
 
No 
 
Yes 
 
Yes 
 
Yes 
L and H 
 
H and L 
neutrophils 
 
NA 
 
H and L 
 
H 
 
H and L 
1 
 
6 
 
 
0 
 
2 
 
1 
 
3 
16 kD HA 
700 
 
710 
 
720 
 
721 
 
762 
 
 
793 
Mild, focal 
 
No inflammation 
 
Mild, focal 
 
Mild, focal 
 
Severe, focal and 
diffuse 
 
Mild, focal 
Yes 
 
NA 
 
No 
 
No 
 
Yes 
 
 
No 
H and L 
 
NA 
 
L 
 
L 
 
H and L 
 
 
L and H 
1 
 
0 
 
1 
 
1 
 
6 
 
 
1 
PLP 
679 
 
709 
 
711 
 
792 
 
795 
Minimal to mild  
 
Mild, focal 
 
Mild, focal 
 
Moderate, focal 
 
No inflammation  
 
No 
 
No 
 
Yes 
 
Yes 
 
NA 
L 
 
L 
 
H and L 
 
H and L 
 
NA 
1 
 
1 
 
1 
 
3 
 
0 
 
LABL 
701 
 
708 
 
719 
 
 
Mild, focal 
 
Mild, focal 
 
Moderate, focal 
and diffuse 
 
Yes 
 
Yes 
 
Yes 
 
 
H and L 
 
H and L 
 
H and L 
 
 
1 
 
1 
 
4 
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723 
 
761 
 
765 
 
 
No inflammation  
 
Mild, focal 
 
Severe, focal and 
diffuse 
NA 
 
Yes 
 
Yes 
NA 
 
H and L 
 
H and L 
0 
 
1 
 
6 
 
 
SAgA 
609 
 
713 
 
717 
 
725 
 
763 
 
799 
Mild, focal   
 
Mild, focal  
 
Mild, focal  
 
No inflammation 
 
Mild, focal  
 
Mild, focal 
 
No 
 
Yes 
 
Yes 
 
NA 
 
Yes 
 
Yes 
L 
 
H and L 
 
H and L 
 
NA 
 
H and L 
 
H and L 
1 
 
1 
 
1 
 
0 
 
1 
 
1 
 
BPI 
703 
 
707 
 
712 
 
724 
 
764 
 
798 
Mild  
 
Mild, focal 
 
No inflammation 
 
No inflammation 
 
Mild, focal 
 
Mild, focal 
 
Yes 
 
Yes 
 
NA 
 
NA 
 
Yes 
 
Yes 
H and L 
 
H and L 
 
NA 
 
NA 
 
H and L 
 
H and L 
2 
 
1 
 
0 
 
0 
 
1 
 
1 
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Treatment 
Days of 
Significance for 
Clinical Scores 
Days of 
Significance for 
Weights 
PBS vs 16 kD HA 12,18,21 12 
PBS vs PLP 12-17 13-18 
PBS vs LABL ns ns 
PBS vs SAgA 12-18,20-25 12-23 
PBS vs BPI 12-16,18-25 13-19 
16 kD HA vs PLP 14,15 14,15 
16 kD HA vs LABL 12,18 12 
16 kD HA vs SAgA 13-17 13-22 
16 kD HA vs BPI 13,14,16 14,15 
PLP vs LABL 12-15,17 13-17 
PLP vs SAgA ns 16-22 
PLP vs BPI ns ns 
LABL vs SAgA 12-19 12-25 
LABL vs BPI 12-18 13-17 
SAgA vs BPI ns 15,16 
 
Supplementary Table 4.1. Two-way ANOVA results comparing all of the groups’ scores 
and weights to each other. 
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Chapter 5: 
Subcutaneous or Pulmonary Delivery of Soluble 
Antigen Arrays to Mitigate Experimental 
Autoimmune Encephalomyelitis 
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5.1 Introduction 
 Antigen-specific immune therapy (ASIT) is an emerging approach for treating 
autoimmune diseases. The idea of inducing immune tolerance originates from classic 
approaches to ASIT, such as allergy shots1. Unfortunately, allergy shots often have 
modest efficacy and require long treatment schedules. Introducing antigen to mucosal 
surfaces may improve efficacy and decrease the amount of time required to induce 
tolerance in the case of ASIT. For example, comparing subcutaneous injections to 
sublingual delivery of allergens, the amount of time to induce tolerance is decreased 
from 3-4 years of injections to 14 months with sublingual therapy2. Since the end goal for 
both ASIT and treatment of autoimmune disease is to induce tolerance, similar 
methodologies may be effective. In fact, we previously reported improved efficacy when 
Soluble Antigen Array (SAgA) were applied to the lungs of mice with experimental 
autoimmune encephalomyelitis (EAE), which is a murine model of multiple sclerosis 
(MS).  
 In the autoimmune disease MS, the immune system identifies myelin sheath as 
‘non-self.’ The resulting neurological symptoms stem from myelin damage, resulting in 
interruptions in signal transduction through axons. One particularly relevant EAE model 
depicts relapsing-remitting MS, since 88% of people with MS have this particular 
subtype3. In order to portray the relapsing-remitting MS subtype of MS, PLP139-151 is the 
epitope used to induce EAE. The same epitope is then used to tolerize the immune 
system against EAE. Thus, PLP is one of the three components of SAgA, the other two 
being LABL and a hyaluorinic acid (HA) backbone to which the peptides are connected. 
LABL binds to ICAM-1, which disrupts interaction between two immune cells4. 
 Previous papers have suggested SAgAs delivered to the lungs via pulmonary 
instillation (PI) may be an effective EAE therapy but it was unclear why the lungs 
improved efficacy5. The lung may be involved with the immune mechanism or may 
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provide improved delivery of SAgAs. For example, the ‘Hub and Spoke’ model states 
that the lung acts as a hub that instructs T cells where to go. In the case of EAE, T cells 
would migrate through the lungs before being deployed to the vasculature of the CNS 
(the spoke)6,7. Additionally, the lungs present a large mucosal surface that may contain 
elements that promote tolerance of inhaled antigen8. Finally, the lung periphery provides 
access to the circulatory system if SAgAs act systemically. Pulmonary delivery 
significantly decreased EAE clinical scores of SAgA or PLP via PI was reported, 
suggesting the antigenic epitope was a key component driving tolerance. To explore this 
further, in this study, mice were either given PLP, SAgA, or HA-PLP, which presents 
PLP as an array. Additionally, mice were given these treatments either via a 
subcutaneous injection or as applied to the mucosal surface in the lungs via PI. Clinical 
scores, mouse weights, cytokine profiles, and lung histology results were compared. 
5.2 Materials and Methods 
5.2.1 Murine EAE Model 
 The animals used were female SJL mice at about 4 weeks old at the beginning of 
the study (Harlan Laboratories, Inc., Indianapolis, IN). The mice were housed in the 
animal facility at the University of Kansas under regulations set by the Association for 
Assessment and Accreditation of Laboratory Care and Institutional and Animal Care and 
Use Committee. On day 0 of the study, mice were subcutaneously injected with a 200 µL 
of emulsion containing incomplete Freund’s Adjuvant (BD Difco Adjuvants, Franklin 
Lakes, NJ), Mycobacterium tuberculosis capsid (BD Difco Adjuvants, Franklin Lakes, 
NJ), and 200 nMol PLP139-151 per animal. They were also given 100 µL of 200 ng of 
pertussis toxin (List Biological Laboratories, Inc., Campbell, CA) via intraperitoneal 
injection on days 0 and 2. All treatments were given on days 4, 7, and 10 of the study. 
The mice were weighed every day of the 26-day study and given clinical scores ranging 
from 0 – 5 starting from day 7. A clinical score of 0 showed no disease symptoms; 1 – 
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tail weakness; 2 – hind leg weakness and partial paralysis; 3 – complete paralysis of 
hind legs (paraplegia); 4 – partial front leg paralysis; and 5 – moribund or complete front 
leg paralysis.  
 A group of 6 mice were treated with subcutaneous delivery of phosphate buffered 
saline (PBS), 200 nMol PLP, HA-PLP, or SAgA (Table 5.1). Similarly, mice were treated 
via pulmonary instillation of 200 nMol PLP, HA-PLP, or SAgA. HA-PLP and SAgA were 
given on a 200 nMol PLP-basis. The subcutaneous injections were at a volume of 100 
µL and the pulmonary instillation was at a volume of 50 µL. In pulmonary instillation, 
each mouse was put under 3% isoflurane in an induction chamber. When the animal 
passed the pinch test, the mouse was suspended on the back via the front teeth, on a 
board at a 60° angle. The tongue was pulled aside using forceps and a laryngoscope 
was used to visualize the trachea and 50 µL of treatment was dispelled to the lungs and 
the mouse was kept at the 60° angle for another minute to allow the liquid to fully enter 
the lung the mouse was monitored while coming out of anesthesia for irregular 
breathing. When the mouse was fully awake and breathing has returned to normal, the 
mouse was returned to its cage. 
5.2.2 SAgA Production and Analysis 
 Hyaluronic acid, 16.9 kD in size, (LifeCore Biomedical, Chaska, MN) was 
hydrated at 2 mg/mL in pH 5.5 acetate buffer. PLP139-151 and LABL (PolyPeptide, Inc., 
San Diego, CA) were added in a ratio of 4 HA monomer repeats to 1 PLP139-151 to 1 
LABL. The pH was adjusted to 5.5 with 0.1-N NaOH and 0.1-N HCl. The reaction was 
left to mix at 400 rpm for 24 hours. The reaction was dialyzed with a membrane 
molecular weight cutoff of 6,000-8,000 Da against purified water for 24 hours. The 
dialysis water was changed every 6 hours, then the reaction mixture was frozen down at 
-80 °C and lyophilized for 3 days. 
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 The SAgAs were dissolved at 1 mg/mL using 0.1-N HCl to be compared against 
varying concentrations of PLP139-151 and LABL (0.0625 – 1 mg/mL, using mobile phase 
A) via RP-HPLC using a C18 Higgins Analytical PROTO200 5 µm, 200 Å, 250 x 4.6 mm2 
column. Mobile Phase A was made of 95% water, 5% acetonitrile, and 0.1% 
trifluoroacetic acid. Mobile Phase B was made of 100% acetonitrile and 0.1% 
trifluoroacetic acid. A gradient used was 100% A from 0 to 15 minutes, 85% A at 15 
minutes, 83% A at 20 minutes, 80% A at 33 minutes, 75% A at 42 minutes, 30% A at 43 
minutes, and 100% A at 46 minutes until 55 minutes with a total flow rate of 1 mL/min. 
An injection volume of 50 µL was used and detection occurred at 220 nm. 
 The hydrodynamic radius of SAgAs was determined using dynamic light 
scattering via ZetaPALS. The samples were made up at a concentration of 1 mg/mL in 
filtered (0.45-µm PVDF) PBS. The samples were filtered once again immediately before 
they were read. Three readings were taken per sample and the average and standard 
deviation were reported. 
5.2.3 Splenocyte Collection 
 Spleens were collected under sterile conditions within a minute after isoflurane 
overdose of mice and were immediately placed in RPMI media with 1% Penicillin-
Streptomycin (P/S) on ice. The spleens were pushed through a wire mesh using the 
rubber end of a 1-mL syringe and a petri dish. The cell mixture was transferred to a 15-
mL Falcon tube using a 5-mL pipette. The cells were centrifuged for 4.5 minutes at 3500 
rpm. After the media was decanted, 1 mL media with serum (RPMI media with 10% fetal 
bovine serum and 1% P/S) and 3.5 mL Gey’s lysis solution was added. The cells were 
then incubated on ice for 3.5 minutes. Ten mL of media with serum was added, and then 
they were centrifuged again at 3500 rpm for 4.5 minutes. Five mL media with serum was 
added and cells were counted using a trypan blue stain and a hemocytometer. The 
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splenocytes were plated at 106 cells/mL with and without 25 µM PLP. The supernatant 
was collected at 120 hours and analyzed for cytokines. 
5.2.4 ELISAs of Cytokines IFN-γ, IL-2, IL-6, IL-10, IL-17, and TNF-α 
 The cytokine panels included IFN-γ, IL-2, IL-6, IL-10, IL-17, and TNF-α using kits 
from R and D Systems. A 100-µL aliquot of the supernatant collected from splenocytes 
at 120 hours was used for IL-2, IL-6, IL-10 and TNF-α. The samples for IFN-γ and IL-17 
were diluted 2.5-fold using PBS for final results. The plates were read using a 
SpectraMax plate reader at an absorbance of 450 nm and 540 nm. The protocol used 
was designated from R and D Systems. 
5.2.5 Lung Histology 
 After the spleens were excised, the lungs were perfused with 10% buffered 
formalin and the trachea was tied off using surgical string. The lungs were stored in 10% 
buffered formalin for 72 hours, then the formalin was exchanged for 70% ethanol for 
another 72 hours. The surgical string was cut off before the tissue was placed in 
cassettes in 70% ethanol. The samples were submitted to the pathology department 
(KIDDRC) at the University of Kansas – Medical Center for embedding in paraffin wax, 
sectioning, and staining with H&E.  
5.3 Results 
5.3.1 Characteristics of Test Articles 
 The characteristics of PLP, HA-PLP, and SAgA were similar to those previously 
reported (Table 5.1)4,5,9. HPLC was used to quantify peptides released from HA at low 
pH, which was then used to calculate the number or peptides per HA chain. HPLC was 
also emplyed to estimate the approximate molecular weights. Finally, DLS provided 
information of the hydrodynamic radii of the different test articles. 
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5.3.2 EAE Study 
 Each of the mice was compared to their weights at day 8, which is the point in 
the study when the mice weighed the most. The percent change in weights was 
compared for each of the treatments (PLP, HA-PLP, SAgA) given subcutaneously (SC), 
or given via pulmonary instillation (PI). When PLP was injected SC, the decrease in 
weight occurred at an earlier time, but the profiles looked very similar. This later onset of 
weight loss was also seen in the groups where HA-PLP or SAgA (LABL:PLP) were given 
via PI. When comparing individual treatments, SC delivery led to a greater loss in weight 
compared to PI. Mice treated with PLP alone had the greatest weight loss. On the other 
hand, both HA-PLP and SAgA treatments exhibited similar weight profiles, whether 
given subcutaneously or via PI (Figure 5.1). 
 Clinical scores trended similarly to weight loss. PI of PLP, HA-PLP, or SAgA 
(LABL:PLP) seemed to induce lower scores and a later onset of disease in the case of 
HA-PLP and SAgA treatments. While there was not a difference between any of the 
subcutaneously treated mice, the treatments of HA-PLP and SAgA appeared to have 
clinical score profiles that trended lower (Figure 5.2). 
 The incidence of disease graph showed how many animals in a group of six were 
affected by the disease, meaning they had a clinical score of 1.5 or higher. Both of the 
groups treated via PI with HA-PLP or SAgA had more disease-free animals. Mice treated 
subcutaneously with SAgA or via PI of PLP had just one disease-free animal out of six. 
Mice in the remaining groups all progressed to scores above 1.5 (Figure 5.3). 
 Another way to provide an overview of the extent of disease is to take the area 
under the curve (AUC) of the clinical scores, as shown in figure 5.4. Compared to the 
PBS-treated control group, the groups treated with subcutaneous HA-PLP, PI HA-PLP, 
and PI SAgA exhibited the lowest AUCs. Additionally, PI SAgA was lower than SC 
SAgA, but not significantly lower than HA-PLP given SC or via PI.  
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5.3.3 Cytokine Panels 
 After the primary splenocytes were incubated with and without PLP, the following 
cytokine levels were measured (Figure 5.5): IFN-γ, IL-2, IL-6, IL-10, IL-17, and TNF-α. 
While there are no significant differences in cytokine levels in IFN-γ, IL-6, and IL10, there 
were differences in IL-2, IL-17 and TNF-α. IL-2 levels were highest in the group that was 
treated with PI PLP alone, even compared to the PBS control group. IL-17 levels were 
also high in the PI PLP group compared to all other treatments, but were not statistically 
significant when compared to the PBS control group. TNF-α levels, on the other hand, 
were decreased in the SC HA-PLP group, in comparison to the PBS control group. 
5.3.4 Lung Histology 
 Histological images of the lungs showed that there were sporadic events in the 
luminal space and tissue thickening. In the mice treated via subcutaneous injection, PLP 
and SAgA had similar lung histology as the PBS control. The lungs of mice treated via PI 
presented some evidence of thickening of tissue denoted by dense regions of pink and 
purple staining. This thickening of the tissue was attributed to inflammation. The mice 
given PLP via PI showed less thickening of tissue than mice treated with HA-PLP and 
SAgA via PI. It should be noted, however, that stains indicative of inflammation were 
sparse and comparisons subjective. 
5.4. Discussion 
5.4.1 EAE Study 
 This study compared different molecular formats of antigen epitope delivery via 
the SC route or via PI. PLP139-151 was used to induce the murine model of relapse 
remitting EAE. Then, ASIT was performed by delivering this same PLP epitope alone, 
PLP grafted to HA, or as PLP and LABL grafted to HA (SAgA) (Table 5.1). PI of HA-PLP 
and SAgA caused the least decrease in weights during the peak of disease. The PBS 
control group showed the greatest weight loss, as expected4,5,9. The same trends were 
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observed in clinical scores. The groups treated with HA-PLP and SAgA via PI exhibited 
significantly lower clinical scores compared to the PBS control group. When considering 
the incidence of disease, the PI HA-PLP and PI SAgA groups also had the most 
disease-free animals (clinical score lower than 1.5). The area under the curve of clinical 
scores plot, however, showed that the mice treated subcutaneously with HA-PLP also 
had low overall disease. Thus, data suggested PLP must be delivered on an array to be 
effective, but PI delivery led to faster and more complete correction.  
5.4.2 Cytokine Panels 
 The cytokines tested in this paper included IFN-γ, IL-2, IL-6, IL-10, IL-17, and 
TNF-α. IL-10 was the only anti-inflammatory cytokine assessed. The remaining 
cytokines are typically considered to be pro-inflammatory. Immune responses can be 
highly complex, however, depending on the number of cytokines tested, tissue assayed, 
and timing. IFN-γ, IL-6, and IL-10 showed no significant differences. This could be 
because the spleens were taken at the end of the study, when the PLP-specific T cells 
would hypothetically be sequestered to the spleen. In this case, splenocytes from 
animals responding to treatment are still likely to produce high levels of these cytokines, 
similar to animals exhibiting disease.  
 IL-2, IL-17, and TNF-α levels expressed significant differences (Figure 5.5). IL-2, 
IL-17, and TNF-α are traditionally identified with pro-inflammatory cytokines, but IL-17 
has been found to act in conjunction with IL-23 to have a regulatory effect. Additionally, 
IL-2 is known to be represent T cell differentiation, which can make it either a pro- or 
anti-inflammatory cytokine depending on if regulatory T cells are also differentiating. The 
PI PLP treated mice had the highest levels of IL-2, but whether this is pro- or anti-
inflammatory is yet to be determined. According to Badawi et al., an increase in IL-2 
levels seen at a period of remission in EAE may indicate proliferation of regulatory T 
cells, thus contributing to immune tolerance10-13. The levels of IL-2 for the remaining 
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groups were similar to each other, which suggests limited T cell differentiation, perhaps 
due to a limited pool of effector cells responding to PLP. 
 TNF-α is known to induce systemic inflammation, and, thus, is a pro-
inflammatory cytokine marker14,15. Since TNF-α was significantly reduced in the SC HA-
PLP group compared to the PBS control group, it may indicate that this treatment 
induced tolerance. There was no significant difference with the rest of the groups, but 
the overall trends within the PI groups may suggest that PLP delivered on an array and 
co-delivered with LABL may decrease TNF-α levels.  
 IL-17 levels were high in the splenocytes of the mice treated with PLP via PI. The 
lowest IL-17 response occurred in the SC SAgA group. In previous studies done by 
Siahaan, et al., a decrease in IL-17 levels was observed when splenocytes were 
harvested on day 35. The clinical scores were also low at this time, indicative of 
remission10,16,17. We also observed a decrease in IL-17 levels as EAE mice approached 
remission. The decrease in IL-17 during remission suggested animals treated with SC 
SAgA group have fewer Th17 cells, which are thought to play a significant role in the 
pathogenesis of EAE18,19.  
 The increase in IL-2 levels of the splenocytes from mice receiving PLP via PI 
indicated that PLP plays a role in inducing tolerance of PLP-induced EAE. The 
splenocytes from the SC SAgA treated mice, however, depicted a decrease in both TNF-
α and IL-17 levels. Thus, it is likely that subcutaneously delivered SAgA may have also 
induced tolerance. Additionally, cytokines can work in conjunction with one another to be 
either pro- or anti-inflammatory. IL-2 in conjunction with IL-10 can behave in an anti-
inflammatory manner, whereas IL-2 with IL-17 may indicate pro-inflammation20,21. Since 
IL-10 levels were not increased in the splenocytes of mice treated with PLP via PI, it may 
be unlikely that IL-2 was acting in conjunction with IL-10 or cytokine differences were not 
detectable due to the small population of antigen-specific effector cells. IL-2 and IL-17 
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levels in splenocytes of mice treated with PLP via PI were both increased, indicating that 
these two cytokines could work in conjunction with each other to be pro-inflammatory. It 
is still unclear if these levels are coming from antigen-specific effector cells or the 
remaining mixed population of the splenocytes. 
5.4.3 Lung Histology 
 The lung tissue was studied as a result of some signs of inflammation observed 
previously. Here, the effect of delivering various ASITs via PI or SC injection was 
assessed. Gross observations suggested there were only very slight differences in 
histology of the lungs of the different treatment groups. Mice treated SC appeared to 
have more luminal space while the PI treated mice presented more thickening of lung 
tissue, which is indicative of inflammation22. Since the mice treated via PI had treatment 
directly applied to the lungs, it is possible that the lung tissue was irritated. In general, 
stains appeared to be more frequent and more pronounced in groups treated via PI 
compared to SC injections. The results were subjective, but supported further 
exploration to determine the immunological mechanism of immunogenicity in the lungs.  
5.5. Conclusions 
 Clinical scores of mice with EAE indicated that HA-PLP and SAgA delivered via 
PI yielded optimal therapy. The weight loss data supported clinical scores, suggesting PI 
of HA-PLP and SAgA were the most optimized treatments. On the other hand, cytokine 
levels derived from mouse splenocytes during disease remission seemed to show that 
mice treated with PLP via PI and mice treated with SAgA subcutaneously may promote 
immune tolerance. Since many cytokines can either behave as pro- or anti- 
inflammatory, future studies should consider a broader set of assays including analysis 
of IL-23 and flow cytometry to determine effector cell populations. Lastly, the lung 
histology results suggested inflammation was increased with mice that were treated via 
PI, however, interpreting histological staining was subjective. Additional studies of lung 
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epithelial cells and pulmonary lymph nodes will help clarify if immunological mechanisms 
in the lungs play an important role in the treatment of EAE.  
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Table 5.1. Depiction of all of the treatments given to mice with EAE. 
Sample Molar Ratio of LABL:PLP:HA 
Approximate 
MW (kDa) 
Dh in 
PBS 
(nm) 
Proteolipid 
Protein  
(PLP139-151) 
 
 
0:10:0 1.5 N/A 
LABL  N/A 1.0 N/A 
HA-PLP 
 
0:24.8:1 55 5.9 ± 1.1 
Soluble Antigen 
Array (SAgA) 
 
24.3:13.5:1 63 6.6 ± 0.5 
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Figure 5.1. Change in weight of all animals as compared to day 8. (A) Overall summary 
of all groups. (B) Comparison of SC PLP and PI PLP. (C) Comparison of SC HA-PLP 
and PI HA-PLP. (D) Comparison of SC SAgA (LABL:PLP) and PI SAgA (LABL:PLP). (E) 
Comparison of SC PLP, SC HA-PLP, and SC SAgA (LABL:PLP). (F) Comparison of PI 
PLP, PI HA-PLP, and PI SAgA (LABL:PLP). Only top half of error bars are shown, which 
represent the standard deviation. There are 6 mice per group. 
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Figure 5.2. Clinical scores of animals throughout the EAE study. (A) Overall summary of 
all groups. (B) Comparison of SC PLP and PI PLP. (C) Comparison of SC HA-PLP and 
PI HA-PLP. (D) Comparison of SC SAgA (LABL:PLP) and PI SAgA (LABL:PLP). (E) 
Comparison of SC PLP, SC HA-PLP, and SC SAgA (LABL:PLP). (F) Comparison of PI 
PLP, PI HA-PLP, and PI SAgA (LABL:PLP). Only top half of error bars are shown, which 
represent the standard deviation. There are 6 mice per group. 
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Figure 5.3. Incidence of disease showing how many animals remained disease free 
(scored 1.5 or higher). 
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Figure 5.4. Average area under the curve of the clinical scores of each of the mice. Only 
top half of error bars are shown, which represent the standard deviation. There are 6 
mice per group.  
* p<0.05 
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Figure 5.5. Cytokines responses of splenocytes when reintroduced to PLP and without 
PLP. Cytokines explored are (A) IFN-γ, (B) IL-2, (C) IL-6, (D) IL-10, (E) IL-17, and (F) 
TNF-α. Only top half of error bars are shown, which represent the standard deviation. 
There are 6 mice per group. 
* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 
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Treatment	  
Days	  of	  Significance	  for	  Clinical	  
Scores	  
Days	  of	  Significance	  for	  
Weights	  
PBS	  Control	  vs	  SC	  PLP	   11-­‐15	   10-­‐12	  
PBS	  Control	  vs	  SC	  HA-­‐
PLP	   11-­‐18	   11-­‐24	  
PBS	  Control	  vs	  SC	  SAgA	   11,	  12,	  14-­‐16	   10-­‐12,	  15-­‐25	  
PBS	  Control	  vs	  PI	  PLP	   11-­‐16	   10-­‐12,	  14-­‐18,	  22-­‐24	  
PBS	  Control	  vs	  PI	  HA-­‐
PLP	   11-­‐16	   10-­‐18,	  23-­‐25	  
PBS	  Control	  vs	  PI	  SAgA	   11-­‐16	   10-­‐-­‐25	  
SC	  PLP	  vs	  SC	  HA-­‐PLP	   12,	  16,	  17	   15-­‐23	  
SC	  PLP	  vs	  SC	  SAgA	   13,	  16	   16-­‐25	  
SC	  PLP	  vs	  PI	  PLP	   13,	  16	   16-­‐23	  
SC	  PLP	  vs	  PI	  HA-­‐PLP	   14,	  16	   13,	  15-­‐20,	  23,	  25	  
SC	  PLP	  vs	  PI	  SAgA	   14,	  16	   12-­‐23	  
SC	  HA-­‐PLP	  vs	  SC	  SAgA	   13,	  14,	  17	   ns	  
SC	  HA-­‐PLP	  vs	  PI	  PLP	   ns	   ns	  
SC	  HA-­‐PLP	  vs	  PI	  HA-­‐PLP	   12	   12,	  13	  
SC	  HA-­‐PLP	  vs	  PI	  SAgA	   12,	  13	   12,	  13	  
SC	  SAgA	  vs	  PI	  PLP	   13,	  14	   ns	  
SC	  SAgA	  vs	  PI	  HA-­‐PLP	   12-­‐14	   12-­‐14	  
SC	  SAgA	  vs	  PI	  SAgA	   12-­‐14	   12-­‐15	  
PI	  PLP	  vs	  PI	  HA-­‐PLP	   12,	  13	   12,	  13	  
PI	  PLP	  vs	  PI	  SAgA	   12-­‐14	   12-­‐14	  
PI	  HA-­‐PLP	  vs	  PI	  SAgA	   ns	   ns	  
 
Supplemental Figure 1. Statistics for clinical scores and change in weights data. 
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Chapter 6: 
Conclusions and Future Directions 
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6.1 Conclusions 
 The optimal way to deliver SAgAs was explored in this thesis. SAgAs were 
developed to include a targeting portion to the therapy, instead of global 
immunosuppression, which occurs with all other existing treatments. The co-delivery of 
PLP and LABL has been found to be effective with BPI, so this technology was used to 
display these peptides in an array, as there is evidence that receptors tend to cluster on 
cells. The three major studies explored in this work are listed here: (1) finding the optimal 
method in which to administer SAgA by varying dose schedule, dose, amount, and 
routes of administration; (2) further exploring the components of SAgA via pulmonary 
delivery and observing the cytokine profiles of splenocytes re-introduced to the antigenic 
PLP; and (3) studying the necessity to deliver PLP as an array and to co-deliver PLP 
with LABL.  
 In chapter 3, SAgA treatment schedule, dose, injection volume, and routes of 
administration were explored in order to ameliorate EAE symptoms. SAgA treatment 
schedule must be such that the dose must be given before symptoms are fully realized. 
Decreasing the dose of SAgA to 50 nMol PLP was not as effective as the typical 200 
nMol dose. Decreasing the injection volume to 20 µL was not as efficacious as the 100 
µL injection volume, as the lower volume likely had limited exposure. 
 Routes of administration were explored as well to show that pulmonary instillation 
decreased clinical scores the most. While the initial goal was to find a way to deliver 
SAgAs to the lymph nodes, no significant differences were seen with the first set of 
administration sites (upper and lower SC, upper and lower IM, and IP), as they all 
showed similar decreases in clinical scores. Additionally, delivering SAgAs IV was also 
similar to the upper SC injection, suggesting that the upper SC injection was also 
delivering SAgAs systemically. Since pulmonary instillation was the best route of 
administration of SAgAs, a ‘Hub and Spoke’ model of the lungs was used to explain this 
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further. In this model, T cells were licensed in the lung, so it is possible that the 
pulmonary delivery allowed SAgAs to interact with the T cells more either within the lung 
or via the lymphatics of the lung. 
 In chapter 4, the individual components of SAgA were further explored via 
pulmonary instillation. SAgAs were once again found to decrease the clinical scores the 
most and also showed weight gain. When PLP was also delivered via PI, the clinical 
scores were decreased, but there was still weight loss in the mice. As a result, the 
cytokine levels were studied to determine if immune tolerance was achieved. When the 
splenocytes of mice treated with SAgA were reintroduced to PLP, the cytokine 
responses showed a significant increase in IFN-γ, IL-6, and IL-17 compared to mice 
treated with PLP. Since there were no differences in TNF-α, IL-2, or IL-10, but there 
were differences in vivo, there may need to be additional testing done. A lot of the 
comparisons made to literature showed that the time point at which the splenocytes are 
taken (during remission or relapse), the time point at which the cytokines are collected 
after reintroduction to PLP in vitro (48 hours, 96 hours, 120 hours), and the tissues 
harvested will give varying cytokine responses. Since it was still difficult to determine if 
tolerance induction occurred with PLP-treated mice or SAgA-treated mice, further 
exploration of the effects of PLP, HA-PLP, and SAgA was carried out in chapter 5. The 
lungs of mice that were treated via SC and PI were also compared via histology. 
 The clinical scores indicated that HA-PLP and SAgA treatments delivered via PI 
decreased scores the most. The change in weight data supported the clinical scores, 
signifying that PI of HA-PLP and SAgA were the optimal treatments. The cytokine 
results, on the other hand, showed that mice treated with PLP via PI and SAgA treated 
SC may induce tolerance. This is based on the increased IL-2 levels for the splenocytes 
of mice treated with PLP via PI and the decreased TNF-α and IL-17 levels in the 
splenocytes of mice treated with SAgA SC. Lung histology, on the other hand, depicted 
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that the mice treated via PI showed signs of increased inflammation, which could be 
because the lung tissue interacted directly with the treatments. There needs to be further 
research done to study the result of multiple cytokines interacting with one another, 
considering individual cytokines that may be either pro- or anti-inflammatory can be the 
opposite when expressed in conjunction with another cytokine. Such is the case with the 
interaction between IL-2 and IL-10. IL-2 was known to be a pro-inflammatory cytokine, 
but IL-10 is an anti-inflammatory cytokine. In conjunction, IL-2 and IL-10 work together to 
increase regulatory T cells, so they seem to work in an anti-inflammatory manner. On 
the other hand, IL-2 and IL-17 are known to indicate an increase in Th17 cells, which are 
known to be pro-inflammatory. In this study, since there was no increase in IL-10, it is 
unlikely that IL-2 was working in conjunction with IL-10 to decrease inflammation. On the 
other hand, there was an increase in IL-2 and IL-17 levels of mice treated with PLP via 
PI, so there may be indications of inflammation, as a result.  
6.2 Future Directions 
 To further explore the mechanism of action of SAgAs, there should be a study 
trafficking SAgAs from the lungs. Some preliminary studies were done in trying to track a 
conjugate of similar molecular weight HA using a near IR dye, IR-820 (Figure 6.1). HA-
IR820 was injected in the upper SC position of the mouse, behind the shoulder blades. 
IR-820 was chosen because it is outside the range of skin autofluorescence. The 
drawback of using this method was that a clear draining was never found. Since the 
injection drained over the axillary lymph nodes, it was difficult to view the signal coming 
from the lymph nodes themselves. Additionally, since the new route of administration to 
explore is pulmonary instillation, the dye cannot be used anymore, since the 
fluorescence intensity would be very low as the signal from IR-820 cannot penetrate 
through the lungs, the rib cage, and the epidermal layer. Radio-labeled HA has been 
further explored in work done by Christopher Kuehl. Radio-labeled SAgA is an option, 
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but each of the separate components would also have to be labeled so they can 
individually be tracked through the body of the mouse. This work would be a separate 
dissertation all on its own. 
 Additional future in vitro work can be done to help determine whether the primary 
splenocytes of treated mice would still be pro-inflammatory when re-introduced to PLP. 
This in vitro work was carried out in the chapters 4 and 5. Lastly, to fully optimize the 
delivery of SAgAs, it would be imperative to study SAgA treatment schedule, amount, 
and injection volume via pulmonary instillation.  
 While in vitro work was completed in chapter 4, there were many differences 
found between this study and what is found in literature. No one protocol is present to 
standardize the testing for inducing tolerance. Ideally, a protocol should be established 
in order to be able to compare splenocyte cytokine levels across different labs in various 
parts of the world. The splenocytes should be taken at one time point, the cytokines 
should be ready at one time point, and corresponding tissues should be taken. Lungs 
should also be re-examined to confirm what the histology results have shown for this 
study. 
 Chapter 5 included more experiments with splenocytes and lung histology, but 
there is more information that other cytokines and a combination of cytokines can 
provide. So far, we have found a link between IL-2 and IL-17, but IL-23 should also be 
studied considering it is another cytokine that works in conjunction with IL-2 as a pro-
inflammatory cytokine in multiple sclerosis. Others in the group are working toward 
finding the effector cell populations via antibody labeling and labeling with fluorescent 
PLP in these mixed splenocyte populations. Using this method to identify effector cells 
and ELISpot as an analytical tool may indicate other signs of tolerance induction in EAE. 
Additionally, the pulmonary lymph nodes and lung tissue should be further assayed to 
determine signs of inflammation. ELISpot can be developed to determine the different 
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cytokines expressed for these tissues as there will be far fewer cells from the lungs and 
lymph nodes in comparison to the spleen. More assays need to be run to properly 
identify if tolerance has been induced in mice with EAE. 
 SAgAs must still be further explored by changing these aspects of the molecule: 
peptide density, peptide ratio (LABL:PLP ratio), and size of backbone. The existing 
chemistry does not allow for a the differences in peptide density and ratio to be 
controllable, but click chemistry has been implemented in making “clickable” SAgAs with 
the hope that the molecular dynamics of SAgA can be further explored by fellow 
Berkland lab members. All three must be tested in vivo, but studying the binding kinetics 
of labeled “clickable” SAgAs with varied peptide density and ratio against Raji B cells or 
splenocytes will be interesting to compare to the data the Berkland lab has accumulated 
with existing SAgAs.  
 The use of clinical scores for EAE studies is very subjective and other ways of 
analyzing the level of paralysis may also be useful for the future. The use of MRI to find 
the number of lesions present in brain and spinal cord tissue would be closer to what is 
used in clinical settings with humans to determine the progression of the disease. 
Furthermore, a balance beam test including a harness to hold up mice with increased 
paralysis could also be implemented in better assessing the level of paralysis. These 
assessments could hopefully pinpoint the level of disease progression in later studies to 
better discriminate which changes in treatment will be most effective. 
 In continuing to bridge the gap between treating mice and humans, pulmonary 
instillation will need to be improved upon. There can be many problems with trying to 
have a human inhale liquid. A possibility is to make SAgAs into a dry, inhalable product, 
but much more research needs to be done to optimize a way to make SAgAs inhalable. 
Lastly, SAgAs can also be expanded to treat other autoimmune diseases once the 
disease-specific antigens and peptides are found. The applications for a tolerance-
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inducing treatment for autoimmune diseases, including multiple sclerosis, using SAgAs 
are endless. 
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Figure 6.1. In vivo imaging of 30 kD HA and 50 kD SAgA with IR-820. The mouse ear 
and forelimb can be seen in most images. Darkened images means complete drainage. 
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